k141_56175_24	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.0	231	387	367	1.71e-25	105
k141_56175_24	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	32.0	231	387	368	1.73e-25	105
k141_56175_24	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	30.7	215	387	357	2.81e-25	104
k141_56175_24	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	30.7	215	387	357	2.81e-25	104
k141_56175_24	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	33.2	229	387	365	2.06e-24	102
k141_56175_24	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	29.6	223	387	380	6.29e-24	100
k141_56175_24	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.6	223	387	380	6.29e-24	100
k141_56175_24	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.5	241	387	381	8.68e-24	100
k141_56175_24	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.5	241	387	381	8.68e-24	100
k141_56175_24	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	31.5	222	387	370	1.04e-23	100
k141_56175_25	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	46.7	227	233	231	1.09e-63	197
k141_56175_25	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.9	237	233	235	1.04e-59	187
k141_56175_25	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	41.2	233	233	232	1.23e-57	181
k141_56175_25	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.8	233	233	232	3.49e-57	180
k141_56175_25	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.6	234	233	231	2.72e-56	178
k141_56175_25	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.3	224	233	232	2.80e-56	178
k141_56175_25	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.2	234	233	231	5.45e-56	177
k141_56175_25	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.2	234	233	231	2.18e-55	176
k141_56175_25	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.2	234	233	231	2.18e-55	176
k141_56175_25	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	39.1	233	233	233	2.32e-55	176
k141_224583_3	NCBI|BAB64566.1|1|1|bexA|bexA|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_MATE_transporter_BexA|AMR|efflux	24.2	289	434	443	3.02e-17	82.4
k141_224583_3	SARG|gb|AAG04750.1|ARO:3004077|PmpM	24.5	245	434	477	3.49e-07	51.2
k141_135236_6	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	30.6	278	974	365	1.56e-28	117
k141_135236_6	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	29.9	284	974	370	4.18e-28	116
k141_135236_6	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	29.9	254	974	380	2.93e-23	102
k141_135236_6	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.9	254	974	380	2.93e-23	102
k141_135236_6	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	25.7	276	974	367	1.94e-22	99.4
k141_135236_6	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	25.7	276	974	368	1.97e-22	99.4
k141_135236_6	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.1	245	974	381	2.34e-22	99.4
k141_135236_6	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.1	245	974	381	2.34e-22	99.4
k141_135236_6	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.9	245	974	381	3.15e-22	99.0
k141_135236_6	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.9	245	974	381	3.15e-22	99.0
k141_135236_7	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	47.8	232	231	239	4.40e-77	231
k141_135236_7	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	46.5	230	231	233	1.19e-75	227
k141_135236_7	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	47.0	232	231	235	3.61e-75	226
k141_135236_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	44.8	230	231	232	4.33e-73	221
k141_135236_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	44.8	230	231	232	4.33e-73	221
k141_135236_7	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	45.6	228	231	231	2.76e-71	216
k141_135236_7	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.9	231	231	231	2.76e-71	216
k141_135236_7	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	45.5	224	231	231	7.85e-71	215
k141_135236_7	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.2	228	231	231	3.17e-70	213
k141_135236_7	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	42.4	229	231	229	5.97e-70	213
k141_135236_56	SARG|gi|554689873|ref|WP_023186409.1|	35.2	219	570	648	7.64e-32	129
k141_135236_56	SARG|gi|489039527|ref|WP_002949857.1|	35.2	219	570	648	7.64e-32	129
k141_135236_56	SARG|gi|446048047|ref|WP_000125902.1|	35.2	219	570	648	7.64e-32	129
k141_135236_56	SARG|gi|959866458|ref|WP_058145168.1|	36.4	206	570	648	4.45e-31	127
k141_135236_56	SARG|gi|446048048|ref|WP_000125903.1|	34.7	219	570	648	5.96e-31	126
k141_135236_56	SARG|gi|555268367|ref|WP_023249730.1|	35.9	206	570	648	7.99e-31	126
k141_135236_56	SARG|gi|1027935297|ref|WP_063809363.1|	35.9	206	570	648	7.99e-31	126
k141_135236_56	SARG|gi|487407385|ref|WP_001675419.1|	35.9	206	570	648	1.07e-30	125
k141_135236_56	SARG|gi|487661511|ref|WP_001751648.1|	35.9	206	570	648	1.07e-30	125
k141_135236_56	SARG|gi|446048030|ref|WP_000125885.1|	35.9	206	570	648	1.07e-30	125
k141_135236_58	SARG|gi|1033064422|ref|WP_064375412.1|	32.1	137	850	648	3.15e-08	56.2
k141_135236_58	SARG|gi|1031824807|ref|WP_064152164.1|	36.2	94	850	646	4.14e-08	55.8
k141_135236_58	SARG|gi|694113840|ref|WP_032455777.1|	36.2	94	850	646	5.44e-08	55.5
k141_135236_58	SARG|gi|556195652|ref|WP_023279140.1|	36.2	94	850	646	5.44e-08	55.5
k141_135236_58	SARG|gi|490295685|ref|WP_004191149.1|	36.2	94	850	646	5.44e-08	55.5
k141_135236_58	SARG|gi|852125444|ref|WP_048290339.1|	36.2	94	850	646	5.44e-08	55.5
k141_135236_58	SARG|gi|1046630742|ref|WP_065696754.1|	36.2	94	850	646	7.16e-08	55.1
k141_135236_58	SARG|gi|556476567|ref|WP_023328168.1|	35.1	94	850	641	1.23e-07	54.3
k141_135236_58	SARG|gi|895895864|ref|WP_048997630.1|	35.1	94	850	644	1.24e-07	54.3
k141_135236_58	SARG|gi|1031835425|ref|WP_064161077.1|	35.1	94	850	646	1.24e-07	54.3
k141_135236_60	SARG|gi|928900436|ref|WP_053931243.1|	30.4	553	583	600	1.17e-80	264
k141_135236_60	SARG|gi|664579989|ref|WP_031094015.1|	30.4	553	583	601	1.19e-80	264
k141_135236_60	SARG|gi|739906046|ref|WP_037756452.1|	31.9	526	583	620	1.84e-80	264
k141_135236_60	SARG|gb|AAC74000.1|ARO:3003950|msbA	33.2	560	583	582	2.09e-80	263
k141_135236_60	SARG|gi|516574297|ref|WP_017949361.1|	31.6	526	583	620	1.38e-79	261
k141_135236_60	SARG|AF170880.4.gene1.p01	29.9	569	583	615	1.79e-78	258
k141_135236_60	SARG|gi|558888514|ref|WP_023543283.1|	29.9	569	583	615	1.79e-78	258
k141_135236_60	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.7	580	583	579	2.24e-77	254
k141_135236_60	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.2	583	583	579	4.76e-75	248
k141_135236_60	SARG|gi|943938624|ref|WP_055567802.1|	30.7	527	583	602	1.55e-74	248
k141_213915_2	SARG|gi|403023847|gb|EJY36064.1|	38.2	186	353	200	3.20e-40	139
k141_213915_2	SARG|gi|452996227|gb|AGG19410.1|	38.2	186	353	252	1.32e-39	139
k141_213915_2	SARG|gi|488259314|ref|WP_002330522.1|	38.2	186	353	268	1.99e-39	139
k141_213915_2	SARG|gi|1036536100|emb|SAM71699.1|	38.2	186	353	268	1.99e-39	139
k141_213915_2	SARG|gi|403219412|emb|CCJ27774.1|	37.5	184	353	268	1.99e-39	139
k141_213915_2	SARG|KF823969.1.gene3.p01	38.2	186	353	268	1.99e-39	139
k141_213915_2	SARG|Q47746	37.1	186	353	268	1.50e-38	137
k141_213915_2	SARG|gi|452996213|gb|AGG19398.1|	37.1	186	353	268	1.50e-38	137
k141_213915_2	SARG|gi|498515090|ref|WP_010815297.1|	37.1	186	353	268	1.50e-38	137
k141_213915_2	SARG|FJ349556.1.gene4.p01	30.3	195	353	233	8.91e-25	99.8
k141_213915_13	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	28.8	208	388	343	2.65e-17	81.3
k141_213915_13	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	28.8	208	388	348	2.77e-17	81.3
k141_213915_13	SARG|AY082011.1.gene6.p01	28.8	226	388	323	3.94e-14	71.6
k141_213915_13	SARG|gi|552942232|ref|WP_023043160.1|	28.8	226	388	323	7.12e-14	70.9
k141_213915_13	SARG|gi|749574782|ref|WP_040203616.1|	24.7	255	388	323	1.29e-13	70.1
k141_213915_13	SARG|gi|740152780|ref|WP_037997109.1|	25.4	244	388	322	3.10e-13	68.9
k141_213915_13	SARG|AAD41881	27.4	226	388	323	1.02e-12	67.4
k141_213915_13	SARG|AAD42183	26.5	215	388	322	1.82e-12	66.6
k141_213915_13	SARG|AAR37059	27.9	226	388	323	1.83e-12	66.6
k141_213915_13	SARG|AAD51059	26.5	215	388	323	3.29e-12	65.9
k141_158084_8	megares|MEG_5148|Drugs|beta-lactam|Class_D_betalactamases|OXA_1	26.5	264	295	346	1.95e-16	77.4
k141_158084_39	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.3	453	531	654	3.29e-34	135
k141_158084_39	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.3	453	531	670	3.56e-34	135
k141_158084_39	SARG|AAB51122	26.3	453	531	670	3.56e-34	135
k141_158084_39	SARG|Q08425	26.3	453	531	641	5.58e-34	135
k141_158084_39	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	26.3	453	531	657	6.07e-34	135
k141_158084_39	SARG|Z21523.gene.p01	26.3	453	531	657	6.07e-34	135
k141_158084_39	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.6	453	531	641	4.90e-32	129
k141_158084_39	SARG|AAZ79478	25.6	453	531	657	5.26e-32	129
k141_158084_39	SARG|Q52360	25.6	453	531	641	6.59e-32	129
k141_158084_39	SARG|P70882	25.6	453	531	641	6.59e-32	129
k141_158084_54	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	32.1	218	233	293	4.95e-37	130
k141_158084_54	SARG|gi|445996710|ref|WP_000074565.1|	27.6	228	233	309	1.62e-25	100
k141_158084_54	SARG|gi|814314593|emb|CKF49145.1|	27.2	228	233	309	8.47e-25	98.6
k141_158084_54	SARG|gi|445996709|ref|WP_000074564.1|	27.2	228	233	309	1.18e-24	98.2
k141_158084_54	SARG|gi|446110087|ref|WP_000187942.1|	27.7	235	233	309	1.18e-24	98.2
k141_158084_54	SARG|gi|895736250|emb|COF64653.1|	27.1	229	233	309	3.16e-24	97.1
k141_158084_54	SARG|gi|445996714|ref|WP_000074569.1|	27.1	229	233	309	3.16e-24	97.1
k141_158084_54	SARG|gi|895808656|emb|COR83787.1|	27.1	229	233	309	6.11e-24	96.3
k141_158084_54	SARG|gi|445996719|ref|WP_000074574.1|	27.1	229	233	309	8.48e-24	95.9
k141_158084_54	SARG|gi|446026113|ref|WP_000103968.1|	27.6	232	233	306	1.57e-23	95.1
k141_158084_70	SARG|gi|486458841|gb|EOE03251.1|	37.9	66	302	237	1.41e-07	50.4
k141_158084_72	SARG|HE999704.1.gene3064.p01	27.6	196	459	241	1.73e-18	83.6
k141_158084_72	SARG|gi|441475675|emb|CCQ25429.1|	28.5	137	459	211	4.78e-11	61.2
k141_158084_81	SARG|AAN28721	49.3	73	386	108	1.48e-16	73.9
k141_102121_3	CARD|gb|AAC16242.1|ARO:3005069|rsmA	43.3	60	73	61	1.04e-14	60.8
k141_12736_4	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.1	227	233	231	7.68e-64	197
k141_12736_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	46.7	227	233	228	9.92e-64	197
k141_12736_4	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.0	228	233	232	1.46e-61	191
k141_12736_4	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	40.7	231	233	233	1.02e-56	179
k141_12736_4	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.3	233	233	235	4.34e-56	177
k141_12736_4	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.9	230	233	232	5.61e-56	177
k141_12736_4	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.9	230	233	232	5.61e-56	177
k141_12736_4	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.7	229	233	231	1.09e-55	176
k141_12736_4	CARD|gb|AAG05188.1|ARO:3005068|ParR	42.0	226	233	235	1.74e-55	176
k141_12736_4	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.3	229	233	231	2.18e-55	176
k141_12736_6	SARG|gi|486458841|gb|EOE03251.1|	40.6	64	299	237	1.71e-08	53.1
k141_12736_10	CARD|gb|AAD51347.1|ARO:3003067|smeS	28.5	270	475	467	1.12e-30	122
k141_12736_10	CARD|gb|BAB38260.1|ARO:3000830|cpxA	25.2	274	475	457	2.34e-17	83.2
k141_12736_10	CARD|gb|CYF42523.1|ARO:3004047|kdpD	25.2	222	475	885	6.07e-17	82.8
k141_12736_15	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	36.3	190	524	373	1.13e-23	101
k141_12736_15	megares|MEG_7543|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	28.1	153	524	281	8.35e-07	49.7
k141_12736_15	megares|MEG_7544|Drugs|Glycopeptide|VanG-type_accessory_protein|VANWG_1	28.1	153	524	281	8.35e-07	49.7
k141_12736_15	NCBI|WP_063856762.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	28.1	153	524	281	8.35e-07	49.7
k141_12736_15	NCBI|WP_021419095.1|1|1|vanW-G|vanW-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-G|AMR|glycopeptide	28.1	153	524	281	8.35e-07	49.7
k141_12736_25	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.7	123	125	228	3.94e-15	67.8
k141_12736_25	CARD|gb|AAG05188.1|ARO:3005068|ParR	29.2	113	125	235	3.13e-12	60.1
k141_12736_29	megares|MEG_1289|Drugs|beta-lactam|Penicillin_binding_protein_regulator|BLAI_1	33.0	115	133	126	7.69e-22	83.2
k141_12736_37	NCBI|AKA30736.1|1|1|cxpE|cxpE||1|CHLORAMPHENICOL|PHENICOL|phenicol_efflux_transporter_CxpE|AMR|phenicol	26.5	358	348	397	2.05e-10	60.5
k141_12736_39	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	45.1	224	230	231	1.28e-61	191
k141_12736_39	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.8	225	230	233	2.20e-60	188
k141_12736_39	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.2	227	230	231	2.35e-59	186
k141_12736_39	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	42.5	228	230	231	6.68e-59	184
k141_12736_39	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.7	227	230	231	6.68e-59	184
k141_12736_39	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.5	228	230	231	6.68e-59	184
k141_12736_39	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.7	227	230	231	1.90e-58	183
k141_12736_39	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	42.4	229	230	232	2.77e-58	183
k141_12736_39	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	42.4	229	230	232	2.77e-58	183
k141_12736_39	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.6	227	230	232	5.54e-58	182
k141_12736_40	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.9	289	493	370	2.64e-24	103
k141_12736_40	SARG|gb|AAG05187.1|ARO:3005067|ParS	24.1	303	493	428	2.77e-24	103
k141_12736_40	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	22.1	289	493	365	3.16e-22	97.1
k141_12736_40	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.9	226	493	359	2.41e-21	94.4
k141_12736_40	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	28.2	241	493	364	3.45e-21	94.0
k141_12736_40	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	28.2	241	493	364	3.45e-21	94.0
k141_12736_40	CARD|gb|AEX49906.1|ARO:3003583|basS	24.1	228	493	477	5.01e-18	85.5
k141_12736_47	SARG|CAG34024	37.4	257	264	287	1.40e-45	153
k141_12736_47	SARG|AB028210.1.gene2.p01	35.7	269	264	284	7.18e-45	151
k141_12736_47	SARG|M55427.1.gene1.p01	34.3	265	264	281	2.87e-43	147
k141_12736_47	megares|MEG_34|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3_1	33.9	271	264	287	2.18e-40	140
k141_12736_47	SARG|CAF33325	33.9	271	264	287	2.18e-40	140
k141_12736_47	megares|MEG_55|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3_1	34.2	272	264	286	2.31e-39	137
k141_12736_47	SARG|M55426.1.gene1.p01	34.2	272	264	286	2.31e-39	137
k141_12736_47	megares|MEG_33|Drugs|Aminoglycosides|Aminoglycoside_N-acetyltransferases|AAC3_1	33.2	271	264	287	4.67e-39	136
k141_12736_47	SARG|CAH58703	33.2	271	264	287	4.67e-39	136
k141_12736_47	SARG|gb|KSC15183.1|ARO:3002537|AAC(3)-IIIb	30.7	261	264	272	1.10e-30	114
k141_12736_49	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	30.0	227	227	229	3.55e-23	92.4
k141_12736_49	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.9	225	227	219	2.24e-21	87.4
k141_12736_49	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.9	225	227	219	3.13e-21	87.0
k141_12736_49	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.9	225	227	220	3.19e-21	87.0
k141_12736_49	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	29.1	223	227	220	3.19e-21	87.0
k141_12736_49	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	28.9	225	227	220	4.45e-21	86.7
k141_12736_50	CARD|gb|AEX49906.1|ARO:3003583|basS	32.1	237	344	477	7.54e-29	115
k141_12736_50	CARD|gb|AAD51347.1|ARO:3003067|smeS	27.5	244	344	467	1.56e-19	88.2
k141_12736_50	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.5	229	344	885	7.49e-13	68.6
k141_12736_51	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	42.5	221	225	255	2.38e-55	176
k141_12736_51	SARG|gi|1035706844|ref|WP_064548272.1|	42.5	221	225	648	3.89e-52	177
k141_12736_51	SARG|gi|1001720867|ref|WP_061274204.1|	41.2	221	225	648	1.45e-51	175
k141_12736_51	SARG|gi|556495988|ref|WP_023343675.1|	41.0	222	225	646	2.73e-51	174
k141_12736_51	SARG|gi|746253210|ref|WP_039301529.1|	40.7	221	225	648	7.48e-51	173
k141_12736_51	SARG|gi|495736522|ref|WP_008461101.1|	40.7	221	225	648	1.04e-50	173
k141_12736_51	SARG|gi|851931792|ref|WP_048222288.1|	40.7	221	225	646	1.41e-50	172
k141_12736_51	SARG|gi|976152237|ref|WP_059310432.1|	40.7	221	225	646	1.41e-50	172
k141_12736_51	SARG|gi|896106549|ref|WP_049136608.1|	40.7	221	225	646	1.41e-50	172
k141_12736_51	SARG|gi|829942568|ref|WP_047368199.1|	40.7	221	225	646	1.41e-50	172
k141_147493_47	SARG|gi|447195835|ref|WP_001273091.1|	29.5	227	215	306	4.91e-26	101
k141_147493_47	SARG|ZP_04081918	27.8	227	215	306	9.55e-26	100
k141_147493_47	SARG|gi|447195836|ref|WP_001273092.1|	29.1	227	215	306	1.33e-25	100
k141_147493_47	SARG|gi|500194536|ref|WP_011867743.1|	28.5	221	215	306	2.58e-25	99.4
k141_147493_65	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	37.3	480	480	1033	1.47e-103	331
k141_147493_65	SARG|gb|AEY83581|ARO:3000510|mupB	37.3	480	480	1033	1.47e-103	331
k141_147493_65	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	35.9	443	480	1024	2.07e-90	295
k141_147493_65	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	35.9	443	480	1024	2.07e-90	295
k141_147493_65	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	35.4	443	480	1024	2.03e-88	290
k141_147493_65	SARG|gb|CAA53189|ARO:3000521|mupA	35.4	443	480	1024	2.03e-88	290
k141_147493_65	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	30.9	486	480	1107	3.53e-57	203
k141_147493_65	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	30.9	486	480	1107	3.53e-57	203
k141_147584_1	SARG|gb|ADO96486.1|ARO:3003953|hmrM	26.0	412	469	464	1.36e-23	102
k141_147584_1	NCBI|AAC23256.1|1|1|hmrM|hmrM|efflux|1|EFFLUX|EFFLUX|sodium-coupled_multidrug_efflux_MATE_transporter_HmrM|AMR|efflux	26.0	412	469	464	1.36e-23	102
k141_147584_1	SARG|gi|485757462|ref|WP_001382958.1|	23.2	375	469	457	8.72e-21	93.6
k141_147584_1	SARG|gi|693104039|ref|WP_032258261.1|	23.5	375	469	457	8.72e-21	93.6
k141_147584_1	SARG|gi|487508322|ref|WP_001706332.1|	23.2	375	469	457	8.72e-21	93.6
k141_147584_1	SARG|gi|487339503|ref|WP_001633039.1|	23.2	375	469	457	8.72e-21	93.6
k141_147584_1	SARG|gi|485854416|ref|WP_001456174.1|	23.2	375	469	457	8.72e-21	93.6
k141_147584_1	SARG|gi|447097694|ref|WP_001174950.1|	23.5	375	469	457	1.17e-20	93.2
k141_147584_1	SARG|gi|545139426|ref|WP_021499212.1|	23.5	375	469	457	1.17e-20	93.2
k141_147584_1	SARG|gi|654659075|ref|WP_028119961.1|	23.2	375	469	457	1.17e-20	93.2
k141_2891_13	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.7	264	488	370	9.55e-20	89.7
k141_2891_13	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	24.7	296	488	365	1.39e-17	83.2
k141_2891_13	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.0	252	488	359	3.62e-13	69.7
k141_2891_13	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	25.2	250	488	357	4.77e-13	69.3
k141_2891_13	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	25.2	250	488	357	4.77e-13	69.3
k141_2891_13	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	25.8	256	488	386	7.49e-13	68.9
k141_2891_13	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.8	256	488	386	7.49e-13	68.9
k141_2891_13	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	24.1	257	488	381	1.30e-12	68.2
k141_2891_13	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	24.1	257	488	381	1.30e-12	68.2
k141_2891_13	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.8	256	488	386	1.33e-12	68.2
k141_2891_14	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.1	225	218	232	3.93e-52	167
k141_2891_14	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.1	225	218	231	4.33e-51	164
k141_2891_14	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.4	218	218	228	5.75e-48	156
k141_2891_14	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.9	227	218	231	2.82e-46	152
k141_2891_14	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.2	227	218	231	7.95e-46	150
k141_2891_14	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.2	227	218	231	7.95e-46	150
k141_2891_14	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.4	217	218	219	1.60e-45	149
k141_2891_14	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.4	229	218	229	3.00e-45	149
k141_2891_14	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.2	231	218	235	9.98e-45	148
k141_2891_14	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.0	216	218	219	3.60e-44	146
k141_2891_28	NCBI|WP_049581834.1|1|1|dfrA45|dfrA45|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA45|AMR|diaminopyrimidine	32.9	164	164	164	7.90e-27	98.2
k141_2891_28	NCBI|WP_038694170.1|1|1|dfrA49|dfrA49|insensitivity|2|diaminopyrimidine|diaminopyrimidine|diaminopyrimidine-resistant_dihydrofolate_reductase_DfrA49|AMR|diaminopyrimidine	39.6	144	164	167	2.97e-24	91.7
k141_2891_28	SARG|gb|WP_197749399.1|ARO:3005349|DfrA38	37.3	134	164	166	7.02e-22	85.5
k141_2891_28	SARG|gb|ASF80997.1|ARO:3005164|dfrA35	33.9	171	164	170	3.31e-20	81.3
k141_2891_28	SARG|gb|AAK64581.1|ARO:3004568|dfrA18	29.9	137	164	184	8.26e-08	48.5
k141_237415_16	SARG|gi|926351744|ref|WP_053683383.1|	39.2	222	584	648	3.66e-43	162
k141_237415_16	SARG|AF170880.4.gene1.p01	37.7	223	584	615	6.77e-41	155
k141_237415_16	SARG|gi|558888514|ref|WP_023543283.1|	37.2	223	584	615	2.31e-40	154
k141_237415_16	SARG|gi|953808775|ref|WP_058042812.1|	39.2	194	584	608	3.99e-40	153
k141_237415_16	SARG|gi|748767925|ref|WP_040019608.1|	35.4	223	584	623	2.13e-39	151
k141_237415_16	SARG|gi|1033151784|ref|WP_064457526.1|	39.9	198	584	614	2.66e-39	151
k141_237415_16	SARG|gi|987887954|ref|WP_060953374.1|	39.9	198	584	614	2.66e-39	151
k141_237415_16	SARG|gi|664304639|ref|WP_030834011.1|	39.9	198	584	614	2.66e-39	151
k141_237415_16	SARG|gi|1011069317|ref|WP_062010695.1|	39.9	198	584	614	2.66e-39	151
k141_237415_16	SARG|gi|663350985|ref|WP_030349761.1|	35.6	222	584	613	4.86e-39	150
k141_237415_24	SARG|gb|AAC75314.1|ARO:3003578|pmrF	32.7	309	322	322	6.47e-45	154
k141_237415_31	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	27.7	177	328	366	9.34e-08	52.0
k141_237415_31	SARG|AAF71281	26.0	173	328	349	4.99e-06	46.6
k141_237415_31	SARG|DQ212986.1.gene8.p01	26.0	173	328	349	6.65e-06	46.2
k141_237415_31	SARG|gi|405945042|pdb|4FU0|A	26.0	173	328	357	6.77e-06	46.2
k141_237415_37	SARG|gi|685229372|ref|WP_031601992.1|	29.4	255	307	660	5.92e-29	115
k141_237415_37	SARG|gi|446571420|ref|WP_000648766.1|	29.4	255	307	660	5.92e-29	115
k141_237415_37	SARG|gi|353570208|gb|EHC34541.1|	29.4	255	307	660	5.92e-29	115
k141_237415_37	SARG|gi|920043689|ref|WP_052939451.1|	29.4	255	307	660	8.04e-29	115
k141_237415_37	SARG|gi|446571412|ref|WP_000648758.1|	29.4	255	307	660	8.04e-29	115
k141_237415_37	SARG|gi|1002387632|ref|WP_061375456.1|	29.4	255	307	660	8.04e-29	115
k141_237415_37	SARG|gi|446571414|ref|WP_000648760.1|	29.4	255	307	660	8.04e-29	115
k141_237415_37	SARG|gi|555286822|ref|WP_023261408.1|	29.4	255	307	660	8.04e-29	115
k141_237415_37	SARG|gi|446571418|ref|WP_000648764.1|	29.4	255	307	660	8.04e-29	115
k141_237415_37	SARG|YP_002115369	29.4	255	307	660	8.04e-29	115
k141_237415_58	SARG|gi|917229923|ref|WP_051836635.1|	37.4	219	603	620	2.27e-40	154
k141_237415_58	SARG|gi|695865802|ref|WP_032778631.1|	35.8	232	603	605	2.66e-40	154
k141_237415_58	SARG|gi|695887424|ref|WP_032788534.1|	35.8	232	603	605	6.66e-40	153
k141_237415_58	SARG|gi|664180077|ref|WP_030714054.1|	35.8	232	603	605	6.66e-40	153
k141_237415_58	SARG|gi|917203192|ref|WP_051809904.1|	37.0	219	603	620	7.71e-40	153
k141_237415_58	SARG|gi|1033217078|gb|OAR27197.1|	32.2	304	603	601	8.68e-40	152
k141_237415_58	SARG|gi|505420018|ref|WP_015607120.1|	35.6	222	603	603	8.86e-40	152
k141_237415_58	SARG|gi|917155568|ref|WP_051762280.1|	37.4	219	603	620	1.05e-39	152
k141_237415_58	SARG|gi|695891735|ref|WP_032792824.1|	36.6	243	603	603	1.20e-39	152
k141_237415_58	SARG|gi|926356413|ref|WP_053687351.1|	36.5	219	603	620	1.42e-39	152
k141_237415_80	SARG|gb|AAC74000.1|ARO:3003950|msbA	28.6	511	597	582	1.97e-49	179
k141_237415_80	SARG|gi|497748188|ref|WP_010062372.1|	36.4	236	597	605	6.19e-40	153
k141_237415_80	SARG|gi|695865802|ref|WP_032778631.1|	36.4	236	597	605	6.19e-40	153
k141_237415_80	SARG|gi|695842130|ref|WP_032755430.1|	37.0	219	597	603	8.24e-40	152
k141_237415_80	SARG|gi|695887424|ref|WP_032788534.1|	36.4	236	597	605	1.55e-39	152
k141_237415_80	SARG|gi|764446018|ref|WP_044369325.1|	36.0	236	597	605	1.55e-39	152
k141_237415_80	SARG|gi|664180077|ref|WP_030714054.1|	36.4	236	597	605	1.55e-39	152
k141_237415_80	SARG|gi|943909899|ref|WP_055545300.1|	35.2	236	597	601	2.75e-39	151
k141_237415_80	SARG|gi|948137056|ref|WP_056795395.1|	37.4	219	597	602	2.77e-39	151
k141_237415_80	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.1	406	597	574	2.80e-39	150
k141_237415_103	SARG|AF139725.gene.p01	35.7	199	231	214	1.17e-31	114
k141_237415_103	SARG|AAF24171	35.2	199	231	214	2.31e-31	113
k141_237415_103	SARG|AAK91782	35.7	199	231	214	2.31e-31	113
k141_237415_103	SARG|AAG21695	35.2	199	231	214	4.57e-31	112
k141_237415_103	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	43.6	140	231	214	6.43e-31	112
k141_237415_103	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	43.6	140	231	214	6.43e-31	112
k141_237415_103	NCBI|WP_063856934.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	43.6	140	231	214	6.43e-31	112
k141_237415_103	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	35.2	199	231	214	1.79e-30	111
k141_237415_103	NCBI|WP_071846347.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	41.7	151	231	210	6.86e-29	107
k141_237415_103	NCBI|WP_071846375.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	41.7	151	231	210	9.63e-29	106
k141_237415_106	SARG|gb|AAC74000.1|ARO:3003950|msbA	30.5	387	604	582	1.17e-49	180
k141_237415_106	SARG|gi|501350226|ref|WP_012381861.1|	40.5	220	604	603	1.65e-46	172
k141_237415_106	SARG|gi|930482089|ref|WP_054228897.1|	42.3	220	604	599	2.15e-46	171
k141_237415_106	SARG|gi|985844137|ref|WP_060895163.1|	42.3	220	604	599	2.15e-46	171
k141_237415_106	SARG|gi|655413091|ref|WP_028811890.1|	40.5	220	604	603	2.26e-46	171
k141_237415_106	SARG|gi|664170108|ref|WP_030704355.1|	40.5	220	604	603	3.10e-46	171
k141_237415_106	SARG|gi|490068471|ref|WP_003970646.1|	40.5	220	604	603	3.10e-46	171
k141_237415_106	SARG|gi|943938624|ref|WP_055567802.1|	40.5	220	604	602	4.18e-46	171
k141_237415_106	SARG|gi|827013130|ref|WP_047175495.1|	41.4	220	604	603	5.80e-46	170
k141_237415_106	SARG|gi|517787730|ref|WP_018957938.1|	40.5	220	604	610	6.35e-46	170
k141_237415_125	SARG|FJ460181.2.gene2.p01	41.6	137	217	210	2.55e-28	105
k141_237415_125	SARG|X82455.1.gene1.p01	40.9	137	217	210	1.40e-27	103
k141_237415_125	SARG|AF418284.1.gene3.p01	40.1	137	217	210	3.88e-27	102
k141_237415_125	SARG|AAS89471	40.9	137	217	210	3.88e-27	102
k141_237415_125	SARG|AY123251.gene2.p01	40.9	137	217	210	3.88e-27	102
k141_237415_125	NCBI|WP_010635894.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	40.9	137	217	210	3.88e-27	102
k141_237415_125	NCBI|WP_021018581.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	40.9	137	217	210	5.45e-27	101
k141_237415_125	NCBI|WP_071766400.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	40.9	137	217	210	5.45e-27	101
k141_237415_125	NCBI|WP_071846284.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	40.9	137	217	210	7.66e-27	101
k141_237415_125	SARG|ABD04054	40.1	137	217	210	2.12e-26	100
k141_237415_150	SARG|U19459.gene.p01	52.7	55	105	212	8.67e-15	65.9
k141_237415_150	SARG|AF015628.1.gene2.p01	37.1	97	105	212	1.70e-14	65.1
k141_237415_150	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	49.3	69	105	210	2.30e-14	64.7
k141_237415_150	SARG|gb|APB03220.1|ARO:3003987|VatI	41.3	92	105	210	3.22e-14	64.3
k141_237415_150	SARG|gb|AAF63432|ARO:3003744|vatF	49.3	67	105	221	3.73e-14	64.3
k141_237415_150	SARG|M58472.1.gene1.p01	44.9	69	105	209	4.44e-14	63.9
k141_237415_150	SARG|ABD04054	43.5	69	105	210	1.23e-13	62.8
k141_237415_150	SARG|YP_001779894	49.1	55	105	212	1.26e-13	62.8
k141_237415_150	SARG|YP_001785579	49.1	55	105	212	1.26e-13	62.8
k141_237415_150	SARG|GQ205627.2.gene3.p01	37.0	100	105	216	1.33e-13	62.8
k141_237415_182	SARG|gb|AAC75314.1|ARO:3003578|pmrF	27.9	312	340	322	1.65e-28	111
k141_237415_219	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.7	213	449	307	1.61e-19	87.8
k141_237415_219	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.1	223	449	255	3.29e-17	80.1
k141_237415_219	SARG|gb|AYV52072.1|ARO:3002882|lmrD	27.5	211	449	664	1.88e-11	65.1
k141_237415_219	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	22.1	249	449	351	3.00e-11	63.5
k141_237415_219	SARG|gb|AAR96051.1|ARO:3002894|otrC	22.1	249	449	351	5.34e-11	62.8
k141_237415_219	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.5	207	449	655	1.00e-10	62.8
k141_237415_219	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.5	207	449	655	1.00e-10	62.8
k141_237415_219	SARG|gi|651595894|ref|WP_026590859.1|	31.1	164	449	492	1.09e-10	62.4
k141_237415_219	SARG|gi|1008988570|ref|WP_061884457.1|	31.7	164	449	492	1.09e-10	62.4
k141_237415_219	SARG|gi|1045390184|ref|WP_065479071.1|	25.7	222	449	605	1.27e-10	62.4
k141_237415_250	CARD|gb|AAG06465.1|ARO:3005063|cprR	27.3	110	517	223	9.36e-07	48.9
k141_47035_66	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.2	219	248	255	3.70e-39	135
k141_47035_66	SARG|gb|APB03219.1|ARO:3003986|TaeA	29.2	233	248	648	1.68e-16	77.4
k141_47035_66	SARG|AAA50325	29.9	211	248	569	2.93e-13	67.8
k141_204406_5	SARG|gb|ANZ79476.1|ARO:3003908|Erm(47)	34.2	184	292	246	3.93e-22	91.7
k141_204406_5	SARG|P45438	29.8	191	292	287	4.18e-22	92.4
k141_204406_5	SARG|Q04720	29.8	191	292	287	5.78e-22	92.0
k141_204406_5	SARG|M29832.gene.p01	29.8	191	292	287	5.78e-22	92.0
k141_204406_5	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	30.4	204	292	243	9.92e-22	90.5
k141_204406_5	SARG|AY234334.1.orf0.gene.p01	33.3	186	292	281	3.66e-21	89.7
k141_204406_5	SARG|gb|QKE44141.1|ARO:3007033|Erm(51)	30.0	263	292	263	6.19e-18	80.5
k141_204406_5	NCBI|WP_046361760.1|1|1|erm(55)|erm(55)|target_modification|2|CLARITHROMYCIN|MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(55)|AMR|macrolide	26.0	265	292	270	2.75e-15	73.2
k141_204406_5	NCBI|WP_311033295.1|1|1|erm(55)|erm(55)|target_modification|2|CLARITHROMYCIN|MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(55)|AMR|macrolide	26.7	258	292	270	3.76e-15	72.8
k141_204406_40	SARG|gi|313614636|gb|EFR88215.1|	29.2	431	447	453	3.11e-68	223
k141_204406_40	SARG|gi|313638554|gb|EFS03703.1|	29.6	426	447	453	4.37e-68	223
k141_204406_40	SARG|gi|488374619|ref|WP_002444004.1|	31.2	429	447	452	4.22e-63	209
k141_204406_40	SARG|gi|686155635|ref|WP_031787393.1|	31.7	436	447	451	1.68e-61	205
k141_204406_40	SARG|gi|446573718|ref|WP_000651064.1|	31.2	436	447	451	6.48e-61	204
k141_204406_40	SARG|gi|505177635|ref|WP_015364737.1|	31.1	425	447	451	6.84e-60	201
k141_204406_40	SARG|gi|686432388|ref|WP_031921070.1|	31.1	425	447	451	1.34e-59	200
k141_204406_40	SARG|ZP_04679156	31.1	425	447	451	1.34e-59	200
k141_204406_40	SARG|gi|686355454|ref|WP_031890196.1|	30.8	425	447	451	1.87e-59	200
k141_204406_40	SARG|gi|516415429|ref|WP_017804827.1|	30.8	425	447	451	1.87e-59	200
k141_47057_1	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	27.2	261	461	380	6.34e-15	75.1
k141_47057_1	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	27.2	261	461	380	6.34e-15	75.1
k141_47057_1	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	20.5	312	461	368	1.43e-13	70.9
k141_47057_1	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	24.2	269	461	370	1.45e-13	70.9
k141_47057_1	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	22.7	256	461	367	2.54e-13	70.1
k141_47057_1	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.1	277	461	381	6.52e-13	68.9
k141_47057_1	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.1	277	461	381	6.52e-13	68.9
k141_47057_1	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	24.8	210	461	357	1.02e-12	68.2
k141_47057_1	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	24.8	210	461	357	1.02e-12	68.2
k141_47057_1	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	24.7	259	461	365	1.07e-12	68.2
k141_47057_2	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.5	227	235	232	2.52e-49	160
k141_47057_2	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.5	227	235	232	2.52e-49	160
k141_47057_2	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.8	226	235	229	9.22e-49	159
k141_47057_2	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.2	233	235	231	3.48e-46	152
k141_47057_2	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.2	238	235	231	2.76e-45	150
k141_47057_2	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.4	222	235	228	7.15e-45	149
k141_47057_2	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.8	238	235	231	1.55e-44	148
k141_47057_2	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.8	238	235	231	2.19e-44	147
k141_47057_2	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	38.0	237	235	233	6.52e-44	146
k141_47057_2	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.8	230	235	231	8.70e-44	146
k141_47057_3	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	55.1	245	261	307	5.98e-78	237
k141_47057_3	SARG|YP_001373621	50.2	243	261	318	1.02e-70	219
k141_47057_3	SARG|gi|447057510|ref|WP_001134766.1|	49.8	243	261	309	2.21e-70	218
k141_47057_3	SARG|gi|446026113|ref|WP_000103968.1|	49.2	246	261	306	2.85e-70	217
k141_47057_3	SARG|gi|507044560|ref|WP_016115614.1|	49.2	246	261	306	5.71e-70	216
k141_47057_3	SARG|gi|445996710|ref|WP_000074565.1|	52.5	219	261	309	6.24e-70	216
k141_47057_3	SARG|P42332	48.0	250	261	306	1.14e-69	216
k141_47057_3	SARG|gi|445996719|ref|WP_000074574.1|	52.5	219	261	309	1.25e-69	216
k141_47057_3	SARG|gi|507035724|ref|WP_016107411.1|	51.6	219	261	309	1.25e-69	216
k141_47057_3	SARG|gi|445996729|ref|WP_000074584.1|	49.8	243	261	309	1.25e-69	216
k141_47057_12	SARG|gi|445996710|ref|WP_000074565.1|	40.1	212	214	309	2.00e-48	159
k141_47057_12	SARG|gi|447195835|ref|WP_001273091.1|	40.1	212	214	306	2.62e-48	159
k141_47057_12	SARG|gi|445996719|ref|WP_000074574.1|	39.6	212	214	309	3.98e-48	159
k141_47057_12	SARG|ZP_04081918	39.6	212	214	306	5.21e-48	158
k141_47057_12	SARG|gi|447195836|ref|WP_001273092.1|	39.6	212	214	306	7.35e-48	158
k141_47057_12	SARG|gi|895736250|emb|COF64653.1|	39.6	212	214	309	7.92e-48	158
k141_47057_12	SARG|gi|446110087|ref|WP_000187942.1|	39.6	212	214	309	7.92e-48	158
k141_47057_12	SARG|gi|445996714|ref|WP_000074569.1|	39.6	212	214	309	7.92e-48	158
k141_47057_12	SARG|gi|895808656|emb|COR83787.1|	39.6	212	214	309	1.12e-47	157
k141_47057_12	SARG|gi|488042066|ref|WP_002113463.1|	40.1	212	214	309	1.58e-47	157
k141_47057_15	CARD|gb|ATC67679.1|ARO:3000838|arlR	38.9	216	224	219	1.06e-50	163
k141_47057_15	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.8	219	224	219	2.75e-45	149
k141_47057_15	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.8	219	224	219	3.89e-45	149
k141_47057_15	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.8	219	224	220	4.00e-45	149
k141_47057_15	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.7	219	224	220	4.00e-45	149
k141_47057_15	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.8	219	224	220	7.99e-45	148
k141_47057_15	SARG|ZP_02848503	38.4	219	224	221	2.92e-42	141
k141_47057_15	CARD|gb|AAG06465.1|ARO:3005063|cprR	32.7	220	224	223	3.57e-34	120
k141_47057_15	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.9	218	224	228	5.70e-34	120
k141_47057_15	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	33.0	221	224	233	7.06e-33	117
k141_47057_16	CARD|gb|ATC67679.1|ARO:3000838|arlR	32.7	217	226	219	1.41e-36	127
k141_47057_16	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.7	207	226	231	2.72e-36	126
k141_47057_16	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.8	207	226	231	5.41e-36	125
k141_47057_16	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	37.0	208	226	229	1.44e-35	124
k141_47057_16	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.3	207	226	231	1.51e-35	124
k141_47057_16	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.3	207	226	231	2.13e-35	124
k141_47057_16	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.4	212	226	235	2.36e-35	124
k141_47057_16	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	37.8	201	226	225	2.57e-35	124
k141_47057_16	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	33.0	200	226	228	8.52e-34	120
k141_47057_16	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	31.6	206	226	230	8.95e-34	120
k141_47057_18	SARG|gi|445996708|ref|WP_000074563.1|	34.0	318	374	309	1.07e-41	147
k141_47057_18	SARG|gi|488068784|ref|WP_002140181.1|	32.5	317	374	309	1.07e-41	147
k141_47057_18	SARG|gi|542061059|gb|ERI11611.1|	33.8	325	374	316	1.27e-41	147
k141_47057_18	SARG|gi|445996710|ref|WP_000074565.1|	33.1	317	374	309	1.50e-41	147
k141_47057_18	SARG|gi|507035724|ref|WP_016107411.1|	33.6	318	374	309	2.93e-41	146
k141_47057_18	SARG|gi|507023808|ref|WP_016095885.1|	31.9	317	374	309	4.10e-41	145
k141_47057_18	SARG|gi|447057510|ref|WP_001134766.1|	32.2	317	374	309	5.73e-41	145
k141_47057_18	SARG|gi|488067981|ref|WP_002139378.1|	31.9	317	374	309	8.01e-41	145
k141_47057_18	SARG|gi|895736250|emb|COF64653.1|	32.8	317	374	309	8.01e-41	145
k141_47057_18	SARG|gi|488130770|ref|WP_002201978.1|	31.9	317	374	309	8.01e-41	145
k141_47057_29	SARG|gi|1016275448|gb|AMX06027.1|	29.1	247	384	646	2.18e-18	85.9
k141_47057_29	SARG|gi|779866095|ref|WP_045354445.1|	28.7	247	384	646	7.00e-18	84.3
k141_47057_29	SARG|gi|556487375|ref|WP_023335108.1|	29.1	247	384	646	1.25e-17	83.6
k141_47057_29	SARG|gi|779956086|ref|WP_045403603.1|	28.7	247	384	646	1.25e-17	83.6
k141_47057_29	SARG|gi|1016942913|ref|WP_063144441.1|	28.7	247	384	646	1.25e-17	83.6
k141_47057_29	SARG|gi|895872463|ref|WP_048979698.1|	28.7	247	384	646	1.25e-17	83.6
k141_47057_29	SARG|gi|1032819400|ref|WP_064325534.1|	27.6	261	384	646	1.25e-17	83.6
k141_47057_29	SARG|gi|695731723|ref|WP_032658224.1|	28.7	247	384	646	1.67e-17	83.2
k141_47057_29	SARG|gi|835749851|ref|WP_047648187.1|	28.7	247	384	646	1.67e-17	83.2
k141_47057_29	SARG|gi|697052471|ref|WP_033145077.1|	28.7	247	384	646	1.67e-17	83.2
k141_47057_30	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	24.4	201	343	550	4.32e-08	53.5
k141_47057_34	SARG|YP_001571041	33.6	238	334	648	7.37e-27	110
k141_47057_34	SARG|gi|960873409|ref|WP_058345546.1|	33.6	238	334	648	7.37e-27	110
k141_47057_34	SARG|gi|740610794|ref|WP_038396317.1|	33.6	238	334	648	1.82e-26	108
k141_47057_34	SARG|gi|835233765|ref|WP_047410073.1|	32.3	260	334	648	4.51e-26	107
k141_47057_34	SARG|gi|446048013|ref|WP_000125868.1|	34.5	238	334	648	6.10e-26	107
k141_47057_34	SARG|gi|754951242|ref|WP_042307417.1|	32.3	260	334	648	1.11e-25	106
k141_47057_34	SARG|gi|507086196|ref|WP_016156937.1|	32.3	260	334	648	1.11e-25	106
k141_47057_34	SARG|gi|922960663|ref|WP_053388845.1|	34.2	231	334	648	1.51e-25	106
k141_47057_34	SARG|gi|922019548|ref|WP_053299973.1|	33.6	238	334	648	2.04e-25	105
k141_47057_34	SARG|gi|923061916|ref|WP_053445667.1|	33.2	238	334	648	2.75e-25	105
k141_47057_35	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	25.5	239	330	574	5.72e-18	83.6
k141_47057_35	SARG|gb|AAK76137.1|ARO:3000024|patA	28.7	216	330	564	2.05e-15	75.9
k141_159763_2	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	31.9	119	367	231	1.09e-10	60.1
k141_159763_12	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	30.6	216	301	293	5.51e-32	119
k141_159763_12	SARG|gi|507044560|ref|WP_016115614.1|	31.3	217	301	306	5.40e-30	114
k141_159763_12	SARG|gi|500448961|gb|EOP61695.1|	31.3	217	301	306	1.46e-29	113
k141_159763_12	SARG|gi|895736250|emb|COF64653.1|	31.8	217	301	309	2.15e-29	112
k141_159763_12	SARG|gi|446110087|ref|WP_000187942.1|	31.8	217	301	309	2.15e-29	112
k141_159763_12	SARG|gi|500465078|gb|EOP76697.1|	31.3	217	301	306	2.82e-29	112
k141_159763_12	SARG|gi|445996709|ref|WP_000074564.1|	31.3	217	301	309	2.99e-29	112
k141_159763_12	SARG|gi|445996714|ref|WP_000074569.1|	31.8	217	301	309	2.99e-29	112
k141_159763_12	SARG|gi|895808656|emb|COR83787.1|	31.3	217	301	309	4.15e-29	112
k141_159763_12	SARG|gi|500194536|ref|WP_011867743.1|	31.9	207	301	306	5.47e-29	111
k141_159763_25	CARD|gb|BAB36671.1|ARO:3000832|evgA	23.2	112	265	204	3.03e-06	45.8
k141_159763_28	SARG|HE999704.1.gene3064.p01	29.8	208	453	241	2.56e-15	74.3
k141_159763_28	SARG|gi|441475675|emb|CCQ25429.1|	28.8	153	453	211	6.36e-08	52.0
k141_159763_33	SARG|YP_001571041	28.7	244	341	648	4.23e-17	81.3
k141_159763_33	SARG|gi|960873409|ref|WP_058345546.1|	28.7	244	341	648	4.23e-17	81.3
k141_159763_33	SARG|gi|922019548|ref|WP_053299973.1|	29.1	244	341	648	5.68e-17	80.9
k141_159763_33	SARG|gi|919601241|ref|WP_052893936.1|	28.7	244	341	648	1.02e-16	80.1
k141_159763_33	SARG|ZP_03074747	28.7	244	341	648	1.02e-16	80.1
k141_159763_33	SARG|gi|740610794|ref|WP_038396317.1|	28.7	244	341	648	1.02e-16	80.1
k141_159763_33	SARG|gi|923061916|ref|WP_053445667.1|	28.7	244	341	648	1.02e-16	80.1
k141_159763_33	SARG|gi|555268367|ref|WP_023249730.1|	28.7	244	341	648	1.37e-16	79.7
k141_159763_33	SARG|gi|1005616587|ref|WP_061695226.1|	28.7	244	341	648	1.37e-16	79.7
k141_159763_33	SARG|gi|1027935297|ref|WP_063809363.1|	28.7	244	341	648	1.37e-16	79.7
k141_159763_34	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.6	233	271	255	1.11e-25	100
k141_159763_34	SARG|gb|AAK76137.1|ARO:3000024|patA	30.3	244	271	564	1.85e-16	77.8
k141_159763_34	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.7	241	271	575	2.40e-13	68.6
k141_159763_34	SARG|gi|930482089|ref|WP_054228897.1|	26.7	236	271	599	5.95e-13	67.4
k141_159763_34	SARG|gi|985844137|ref|WP_060895163.1|	26.7	236	271	599	5.95e-13	67.4
k141_159763_34	SARG|gi|764446018|ref|WP_044369325.1|	26.2	252	271	605	5.97e-13	67.4
k141_159763_34	SARG|gi|695865802|ref|WP_032778631.1|	26.2	252	271	605	5.97e-13	67.4
k141_159763_34	SARG|gi|1045390184|ref|WP_065479071.1|	25.4	252	271	605	5.97e-13	67.4
k141_159763_34	SARG|gi|739906046|ref|WP_037756452.1|	26.7	225	271	620	6.03e-13	67.4
k141_159763_34	SARG|gi|516574297|ref|WP_017949361.1|	26.7	225	271	620	6.03e-13	67.4
k141_69660_15	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	26.8	142	211	342	5.33e-12	62.8
k141_69660_15	SARG|gb|WP_122630831.1|ARO:3006864|CRD3-1	29.4	143	211	303	3.91e-11	60.1
k141_69660_15	SARG|gb|AJP77059|ARO:3003670|PEDO-1	27.0	137	211	286	9.02e-11	58.9
k141_69660_15	NCBI|WP_015048279.1|1|1|blaSAM-1|blaSAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_SAM-1|AMR|beta-lactam	32.8	128	211	295	1.29e-10	58.5
k141_69660_15	SARG|gb|WP_041884311.1|ARO:3006972|PLN-1	33.0	103	211	289	2.31e-10	57.8
k141_69660_15	SARG|EU408354.1.gene5.p01	27.5	138	211	294	2.37e-10	57.8
k141_69660_15	SARG|gb|WP_081853183.1|ARO:3006885|ELM-1	27.5	160	211	313	2.56e-10	57.8
k141_69660_15	SARG|gb|AYD68552.1|ARO:3005018|LMB-1	37.8	90	211	304	6.19e-10	56.6
k141_69660_15	NCBI|WP_111263186.1|1|1|blaPAM-3|blaPAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PAM-3|AMR|beta-lactam	30.2	106	211	287	1.01e-07	50.1
k141_69660_15	NCBI|WP_173179784.1|1|1|blaPAM-2|blaPAM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3_metallo-beta-lactamase_PAM-2|AMR|beta-lactam	30.2	106	211	287	1.85e-07	49.3
k141_69660_24	CARD|gb|WKR28567.1|ARO:3007678|IreK	35.0	637	713	718	1.02e-88	292
k141_182388_11	SARG|AUI09862.1	44.6	271	276	287	1.19e-79	241
k141_182388_11	SARG|AJ459418.gene.p01	36.0	261	276	263	9.69e-47	156
k141_182388_11	SARG|gi|970263436|ref|WP_058647620.1|	36.0	261	276	263	1.37e-46	155
k141_182388_11	SARG|gi|553729091|ref|WP_023063817.1|	33.3	246	276	271	2.02e-36	129
k141_182388_11	SARG|gi|638947703|ref|WP_024439711.1|	33.3	246	276	271	2.83e-36	129
k141_182388_11	SARG|gi|504199703|ref|WP_014386805.1|	32.9	246	276	271	5.57e-36	128
k141_182388_11	SARG|gi|550552396|ref|WP_022631488.1|	32.9	246	276	271	7.82e-36	128
k141_182388_11	SARG|gi|916164813|ref|WP_050960181.1|	32.9	246	276	271	7.82e-36	128
k141_182388_11	SARG|gi|835825825|ref|WP_047670793.1|	33.3	246	276	271	1.10e-35	127
k141_182388_11	SARG|gb|AAL59753.1|ARO:3000412|sul2	32.9	246	276	271	1.54e-35	127
k141_216549_1	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.7	122	162	885	7.98e-10	55.5
k141_216549_6	SARG|gb|CAE00499.1|ARO:3003835|cdeA	37.6	434	442	441	2.64e-94	290
k141_216549_8	SARG|gb|CAE00499.1|ARO:3003835|cdeA	25.4	413	451	441	7.10e-37	139
k141_216549_8	SARG|gi|488374619|ref|WP_002444004.1|	24.2	450	451	452	2.61e-34	132
k141_216549_8	SARG|YP_302230	24.7	449	451	451	3.23e-33	129
k141_216549_8	SARG|gi|686396521|ref|WP_031908504.1|	24.1	448	451	451	1.93e-31	124
k141_216549_8	SARG|gi|487135741|ref|WP_001627648.1|	24.1	448	451	451	1.93e-31	124
k141_216549_8	SARG|gi|686367913|ref|WP_031894914.1|	24.1	448	451	451	2.64e-31	124
k141_216549_8	SARG|Q99WP2	24.1	448	451	451	3.61e-31	123
k141_216549_8	SARG|gi|516415429|ref|WP_017804827.1|	23.9	448	451	451	3.61e-31	123
k141_216549_8	SARG|gi|446573715|ref|WP_000651061.1|	23.7	455	451	451	3.61e-31	123
k141_216549_8	SARG|gi|686302738|ref|WP_031866896.1|	24.1	448	451	451	3.61e-31	123
k141_47541_8	SARG|gb|AAC75314.1|ARO:3003578|pmrF	27.1	214	237	322	1.06e-11	62.4
k141_3908_4	CARD|gb|WKR28567.1|ARO:3007678|IreK	34.9	272	291	718	2.42e-31	122
k141_3908_15	megares|MEG_1289|Drugs|beta-lactam|Penicillin_binding_protein_regulator|BLAI_1	37.4	115	130	126	7.32e-27	95.9
k141_3908_15	NCBI|WP_000196386.1|1|1|mecI_of_mecC|mecI_of_mecC||2|METHICILLIN|beta-lactam|mecC-type_methicillin_resistance_repressor_MecI|AMR|beta-lactam	36.3	113	130	124	3.62e-24	89.0
k141_3908_16	CARD|gb|ABU39979.1|ARO:3000217|blaR1	34.8	581	627	588	4.65e-111	344
k141_3908_16	NCBI|WP_012705551.1|1|1|blaR1_gen|blaR1_gen|regulation|2|beta-lactam|beta-lactam|BlaR1_family_beta-lactam_sensor/signal_transducer|AMR|beta-lactam	31.8	611	627	593	5.27e-94	300
k141_3908_16	megares|MEG_3786|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	29.6	608	627	585	2.83e-90	290
k141_3908_16	NCBI|WP_000952923.1|1|1|mecR1|mecR1|regulation|2|METHICILLIN|beta-lactam|beta-lactam_sensor/signal_transducer_MecR1|AMR|beta-lactam	29.6	608	627	585	2.83e-90	290
k141_3908_16	NCBI|WP_001096392.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	29.3	621	627	585	5.96e-73	244
k141_3908_16	NCBI|WP_063842869.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	28.8	621	627	585	5.96e-73	244
k141_3908_16	NCBI|WP_001096376.1|1|1|blaR1|blaR1|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	28.8	621	627	585	8.31e-73	244
k141_3908_16	NCBI|WP_001096386.1|1|1|blaR1-2|blaR1-2|regulation|2|beta-lactam|beta-lactam|beta-lactam_sensor/signal_transducer_BlaR1|AMR|beta-lactam	29.1	621	627	585	8.48e-72	241
k141_3908_16	NCBI|WP_075071939.1|1|1|blaOXA-1089|blaOXA-1089_fam|hydrolase|2|CARBAPENEM|beta-lactam|carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-1089|AMR|beta-lactam	36.4	242	627	289	2.77e-50	175
k141_3908_16	SARG|gb|EIM09515.1|ARO:3004747|BAT-1	32.8	271	627	268	1.39e-44	159
k141_3908_21	SARG|gb|BAI83385.1|ARO:3003440|mecB	30.1	83	99	674	2.74e-07	45.8
k141_3908_21	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	30.1	83	99	674	3.75e-07	45.4
k141_3908_21	SARG|gb|AQX82857.1|ARO:3004185|mecD	30.3	76	99	678	1.78e-06	43.5
k141_138027_35	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	33.5	212	290	343	1.47e-25	102
k141_138027_35	SARG|gb|AAA26793|ARO:3003748|oleC	31.4	245	290	325	1.52e-24	99.8
k141_138027_35	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	31.4	245	290	325	1.52e-24	99.8
k141_138027_35	SARG|gi|895736250|emb|COF64653.1|	29.3	225	290	309	5.85e-23	95.1
k141_138027_35	SARG|gi|446110087|ref|WP_000187942.1|	29.3	225	290	309	5.85e-23	95.1
k141_138027_35	SARG|gi|445996714|ref|WP_000074569.1|	29.3	225	290	309	5.85e-23	95.1
k141_138027_35	SARG|gi|445996696|ref|WP_000074551.1|	29.0	224	290	309	8.08e-23	94.7
k141_138027_35	SARG|gi|445996719|ref|WP_000074574.1|	28.9	225	290	309	1.54e-22	94.0
k141_138027_35	SARG|gi|488042066|ref|WP_002113463.1|	29.3	225	290	309	1.54e-22	94.0
k141_138027_35	SARG|gi|445996729|ref|WP_000074584.1|	28.9	225	290	309	2.13e-22	93.6
k141_138027_36	SARG|gi|445996719|ref|WP_000074574.1|	31.5	222	281	309	1.38e-27	107
k141_138027_36	SARG|gi|445996709|ref|WP_000074564.1|	31.3	233	281	309	7.18e-27	105
k141_138027_36	SARG|gi|500448961|gb|EOP61695.1|	30.2	222	281	306	1.83e-26	104
k141_138027_36	SARG|gi|445996723|ref|WP_000074578.1|	31.1	222	281	309	1.93e-26	104
k141_138027_36	SARG|gi|445996710|ref|WP_000074565.1|	30.9	233	281	309	2.67e-26	103
k141_138027_36	SARG|gi|445996722|ref|WP_000074577.1|	30.6	222	281	309	2.67e-26	103
k141_138027_36	SARG|gi|445996729|ref|WP_000074584.1|	31.1	222	281	309	3.71e-26	103
k141_138027_36	SARG|gi|895736250|emb|COF64653.1|	30.9	233	281	309	3.71e-26	103
k141_138027_36	SARG|gi|446110087|ref|WP_000187942.1|	30.9	233	281	309	3.71e-26	103
k141_138027_36	SARG|gi|500465078|gb|EOP76697.1|	30.2	222	281	306	4.90e-26	103
k141_250080_18	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	31.2	231	542	307	1.87e-24	102
k141_250080_18	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	28.2	234	542	255	4.34e-20	89.0
k141_250080_18	SARG|gb|ADZ12699.1|ARO:3005091|RanA	27.6	228	542	258	3.85e-19	86.3
k141_250080_18	SARG|gi|542061059|gb|ERI11611.1|	24.8	230	542	316	5.37e-14	72.0
k141_250080_18	SARG|gi|445996719|ref|WP_000074574.1|	26.5	223	542	309	9.01e-14	71.2
k141_250080_18	SARG|gi|507050365|ref|WP_016121371.1|	26.0	223	542	309	1.21e-13	70.9
k141_250080_18	SARG|gi|446026113|ref|WP_000103968.1|	24.7	223	542	306	1.57e-13	70.5
k141_250080_18	SARG|gi|488067981|ref|WP_002139378.1|	26.0	223	542	309	2.18e-13	70.1
k141_250080_18	SARG|gi|487936534|ref|WP_002010000.1|	26.0	223	542	309	2.18e-13	70.1
k141_250080_18	SARG|gi|447057509|ref|WP_001134765.1|	26.0	223	542	309	2.92e-13	69.7
k141_250080_26	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	28.5	130	523	228	4.35e-06	47.0
k141_250080_37	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	34.0	285	320	323	1.47e-34	127
k141_250080_37	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	32.3	266	320	314	1.29e-32	122
k141_250080_37	SARG|DQ018711.1.gene4.p01	31.2	317	320	322	1.53e-31	119
k141_250080_37	SARG|gi|738848198|ref|WP_036737307.1|	31.2	317	320	323	1.56e-31	119
k141_250080_37	SARG|KF478993.1.gene2.p01	30.9	278	320	350	9.46e-31	117
k141_250080_37	SARG|gi|552942232|ref|WP_023043160.1|	31.4	306	320	323	1.57e-30	116
k141_250080_37	SARG|gi|740152780|ref|WP_037997109.1|	29.9	331	320	322	2.14e-30	116
k141_250080_37	SARG|YP_002333394	31.7	284	320	323	3.03e-30	115
k141_250080_37	SARG|FJ349556.1.gene5.p01	31.7	290	320	326	6.18e-30	115
k141_250080_37	SARG|AY082011.1.gene6.p01	31.0	306	320	323	1.13e-29	114
k141_70576_6	SARG|gb|ABA71733.1|ARO:3002972|vanTG	34.5	374	397	712	2.05e-65	220
k141_70576_6	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	30.9	375	397	366	1.97e-53	180
k141_70576_6	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	30.8	373	397	711	1.87e-49	176
k141_70576_6	SARG|AAY67970	31.4	363	397	698	5.95e-49	175
k141_70576_6	SARG|AF162694.1.gene4.p01	31.4	363	397	698	5.95e-49	175
k141_70576_6	SARG|gi|657686198|ref|WP_029487032.1|	31.4	363	397	698	5.95e-49	175
k141_70576_6	NCBI|WP_063856756.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	34.8	330	397	700	8.35e-49	174
k141_70576_6	NCBI|WP_063856755.1|1|1|vanT-C|vanT-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-C|AMR|glycopeptide	33.7	365	397	700	4.12e-48	172
k141_70576_6	NCBI|WP_063856759.1|1|1|vanTc3|vanTc3|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	33.9	330	397	700	7.65e-44	160
k141_70576_6	NCBI|WP_063856758.1|1|1|vanTc2|vanTc2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT|AMR|glycopeptide	32.1	365	397	706	2.05e-43	159
k141_70576_10	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	625	636	655	9.59e-119	367
k141_70576_10	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	625	636	655	9.59e-119	367
k141_70576_10	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	625	636	655	1.90e-118	366
k141_70576_10	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	625	636	655	2.67e-118	365
k141_70576_10	SARG|gb|AKA86814|ARO:3003746|optrA	34.2	625	636	655	2.67e-118	365
k141_70576_10	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	625	636	655	5.30e-118	365
k141_70576_10	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	625	636	655	5.30e-118	365
k141_70576_10	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	625	636	655	5.30e-118	365
k141_70576_10	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.4	625	636	655	5.30e-118	365
k141_70576_10	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	34.2	625	636	655	5.30e-118	365
k141_70576_21	SARG|YP_002850805	25.9	675	698	652	2.21e-57	205
k141_70576_21	SARG|ZP_02632674	25.1	682	698	660	3.16e-56	202
k141_70576_21	SARG|ZP_02952732	25.3	675	698	652	5.27e-56	201
k141_70576_21	SARG|L20800.gene.p01	25.3	675	698	652	5.27e-56	201
k141_70576_21	SARG|NP_348076	25.1	668	698	652	9.06e-55	197
k141_70576_21	SARG|Q08425	23.7	671	698	641	7.36e-49	181
k141_70576_21	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	23.7	671	698	657	9.02e-49	181
k141_70576_21	SARG|Z21523.gene.p01	23.7	671	698	657	9.02e-49	181
k141_70576_21	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	23.7	671	698	654	2.20e-48	179
k141_70576_21	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	23.7	671	698	670	2.66e-48	179
k141_70576_60	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.6	114	232	228	4.46e-07	48.1
k141_161099_17	SARG|CAD36021	41.3	276	272	264	1.84e-52	171
k141_161099_17	SARG|YP_424819	41.3	276	272	261	2.39e-52	170
k141_161099_17	SARG|CAA67773	41.3	276	272	264	2.60e-52	170
k141_161099_17	SARG|AAK62562	41.3	276	272	264	2.60e-52	170
k141_161099_17	SARG|P0A3Y6	41.1	270	272	263	1.12e-50	166
k141_161099_17	SARG|BAE98117	39.9	276	272	264	1.58e-47	158
k141_161099_17	NCBI|WP_318245542.1|1|1|aph(3')-H510|aph(3')-H510|phosphotransferase|2|KANAMYCIN|aminoglycoside|aminoglycoside_O-phosphotransferase_APH(3')-H510|AMR|aminoglycoside	33.2	259	272	249	2.28e-39	136
k141_161099_17	SARG|M29953.1.gene1.p1	35.7	221	272	250	2.77e-37	131
k141_161099_17	NCBI|WP_004206941.1|1|1|aphA16|aphA16|phosphotransferase|2|AMIKACIN/KANAMYCIN|aminoglycoside|APH(3')_family_aminoglycoside_O-phosphotransferase_AphA16|AMR|aminoglycoside	31.6	225	272	262	9.70e-33	119
k141_161099_17	SARG|0910185A	36.4	220	272	262	1.91e-32	119
k141_138434_3	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	53.2	1234	1293	1162	0.0	1208
k141_138434_3	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	50.5	1259	1293	1186	0.0	1150
k141_138434_3	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	50.5	1259	1293	1186	0.0	1150
k141_250685_5	SARG|gb|AVI44920.1|ARO:3004470|poxtA	30.8	532	547	542	6.46e-65	219
k141_250685_5	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	30.8	532	547	544	6.74e-65	219
k141_250685_5	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.3	519	547	655	2.17e-64	221
k141_250685_5	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.1	519	547	655	2.17e-64	221
k141_250685_5	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.1	519	547	655	3.02e-64	220
k141_250685_5	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	3.02e-64	220
k141_250685_5	SARG|gb|AKA86814|ARO:3003746|optrA	28.9	519	547	655	3.02e-64	220
k141_250685_5	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	8.07e-64	219
k141_250685_5	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	8.07e-64	219
k141_250685_5	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	28.9	519	547	655	8.07e-64	219
k141_184252_11	SARG|ZP_04528247	68.6	274	275	279	1.39e-125	357
k141_184252_11	SARG|ZP_03958019	66.4	283	275	317	2.08e-124	356
k141_184252_11	SARG|YP_002937728	68.0	281	275	289	7.11e-121	346
k141_184252_11	SARG|YP_002929946	65.7	274	275	282	2.02e-116	334
k141_184252_11	SARG|ZP_04433866	62.0	266	275	288	1.06e-105	307
k141_184252_11	SARG|ZP_03984017	62.0	266	275	288	1.50e-105	307
k141_184252_11	SARG|ZP_03949893	61.7	266	275	288	4.27e-105	306
k141_184252_11	SARG|ZP_03938934	56.0	273	275	288	5.00e-94	278
k141_184252_11	SARG|ZP_03941859	55.7	273	275	288	4.06e-93	275
k141_184252_11	SARG|ZP_03945515	53.5	275	275	291	2.38e-90	268
k141_184252_42	SARG|gi|502669352|ref|WP_012905216.1|	39.6	222	244	648	3.58e-40	145
k141_184252_42	SARG|gi|803568669|ref|WP_046077412.1|	39.5	220	244	648	3.33e-39	142
k141_184252_42	SARG|gi|446110352|ref|WP_000188207.1|	39.5	220	244	648	3.33e-39	142
k141_184252_42	SARG|YP_002382193	39.5	220	244	648	3.33e-39	142
k141_184252_42	SARG|gi|803575554|ref|WP_046081557.1|	39.5	220	244	648	3.33e-39	142
k141_184252_42	SARG|gi|446110351|ref|WP_000188206.1|	39.5	220	244	648	3.33e-39	142
k141_184252_42	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	37.0	208	244	255	2.55e-38	133
k141_184252_42	SARG|gi|736472622|ref|WP_034494292.1|	38.6	220	244	648	3.55e-36	134
k141_184252_42	SARG|gi|1035670474|ref|WP_064517458.1|	38.2	220	244	648	1.72e-35	132
k141_184252_42	SARG|gi|1035717981|ref|WP_064557480.1|	38.2	220	244	648	1.72e-35	132
k141_139118_29	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	32.1	439	431	444	3.37e-56	191
k141_139118_49	SARG|gb|AAK76137.1|ARO:3000024|patA	27.9	233	262	564	3.13e-15	73.9
k141_139118_49	SARG|AXF35727.1	26.1	199	262	497	2.06e-06	47.4
k141_139118_49	SARG|gi|494215524|ref|WP_007131565.1|	24.7	186	262	492	6.54e-06	45.8
k141_139118_54	SARG|gi|445996710|ref|WP_000074565.1|	30.0	287	324	309	3.05e-36	131
k141_139118_54	SARG|gi|445996719|ref|WP_000074574.1|	29.3	287	324	309	1.62e-35	129
k141_139118_54	SARG|P42332	32.1	218	324	306	8.58e-33	122
k141_139118_54	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	32.1	218	324	306	8.58e-33	122
k141_139118_54	SARG|gi|510143239|gb|AGN36970.1|	32.1	218	324	313	9.90e-33	122
k141_139118_54	SARG|ABB80128	32.1	218	324	306	1.20e-32	122
k141_139118_54	SARG|AAD21213	28.6	255	324	306	3.24e-32	120
k141_139118_54	SARG|gi|500448961|gb|EOP61695.1|	28.6	287	324	306	6.29e-32	120
k141_139118_54	SARG|gi|500465078|gb|EOP76697.1|	28.2	287	324	306	6.38e-31	117
k141_139118_54	SARG|gi|507044560|ref|WP_016115614.1|	27.5	287	324	306	3.33e-30	115
k141_127611_1	NCBI|WP_002294513.1|1|1|lsa(E)|lsa(E)|target_protection|2|LINCOSAMIDE/STREPTOGRAMIN|LINCOSAMIDE/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_Lsa(E)|AMR|multidrug	50.4	528	529	494	3.54e-175	502
k141_127611_1	SARG|gi|499132967|ref|WP_010860999.1|	47.0	526	529	492	1.21e-167	483
k141_127611_1	SARG|gi|651595894|ref|WP_026590859.1|	47.3	528	529	492	1.21e-167	483
k141_127611_1	SARG|gi|944535691|ref|WP_055747198.1|	47.9	528	529	492	1.72e-167	482
k141_127611_1	SARG|gi|1032346815|ref|WP_064200323.1|	47.9	528	529	492	2.44e-167	482
k141_127611_1	SARG|gi|926256269|ref|WP_053594535.1|	46.8	528	529	492	9.82e-167	480
k141_127611_1	SARG|gi|953356378|ref|WP_058006334.1|	46.6	528	529	492	1.97e-166	479
k141_127611_1	SARG|gi|924348018|ref|WP_053483923.1|	46.6	528	529	492	1.97e-166	479
k141_127611_1	SARG|gi|498488199|ref|WP_010789887.1|	46.8	528	529	492	1.97e-166	479
k141_127611_1	SARG|gi|1027702639|ref|WP_063637955.1|	46.8	528	529	492	1.97e-166	479
k141_127611_3	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	32.9	240	309	343	2.38e-33	124
k141_127611_3	SARG|gb|AAA26793|ARO:3003748|oleC	33.2	211	309	325	1.77e-30	116
k141_127611_3	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	33.2	211	309	325	1.77e-30	116
k141_127611_3	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	33.2	217	309	293	2.58e-30	115
k141_127611_3	megares|MEG_2670|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|DRRA_1	31.5	203	309	293	6.25e-22	92.4
k141_127611_3	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	29.8	228	309	351	1.32e-18	84.0
k141_127611_3	SARG|gb|AAR96051.1|ARO:3002894|otrC	29.8	228	309	351	1.80e-18	83.6
k141_6256_5	CARD|gb|BAE77778.1|ARO:3000508|gadX	27.1	96	537	274	3.51e-06	47.8
k141_27867_5	SARG|gb|AAK76137.1|ARO:3000024|patA	23.1	229	501	564	6.54e-11	63.5
k141_27867_5	SARG|gi|739906046|ref|WP_037756452.1|	24.6	224	501	620	2.04e-06	49.3
k141_27867_5	SARG|gi|516574297|ref|WP_017949361.1|	24.6	224	501	620	2.69e-06	48.9
k141_27867_5	SARG|gi|944152509|ref|WP_055644808.1|	24.1	232	501	616	8.13e-06	47.4
k141_27867_17	SARG|gi|740856590|ref|WP_038641842.1|	38.7	235	357	648	4.78e-44	159
k141_27867_17	SARG|gi|851928815|ref|WP_048221086.1|	38.3	235	357	648	3.25e-43	157
k141_27867_17	SARG|gi|780033092|ref|WP_045444768.1|	38.3	235	357	648	3.25e-43	157
k141_27867_17	SARG|gi|507050365|ref|WP_016121371.1|	33.5	233	357	309	4.97e-32	121
k141_27867_17	SARG|gi|488053456|ref|WP_002124853.1|	33.5	233	357	309	4.97e-32	121
k141_27867_17	SARG|gi|488067981|ref|WP_002139378.1|	33.5	233	357	309	9.61e-32	120
k141_27867_17	SARG|gi|487936534|ref|WP_002010000.1|	33.5	233	357	309	9.61e-32	120
k141_27867_17	SARG|gi|488130770|ref|WP_002201978.1|	33.5	233	357	309	1.34e-31	120
k141_27867_17	SARG|gi|507023808|ref|WP_016095885.1|	33.0	233	357	309	1.34e-31	120
k141_27867_17	SARG|gi|500448961|gb|EOP61695.1|	33.1	236	357	306	2.43e-31	119
k141_27867_28	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	33.9	227	513	307	6.76e-28	112
k141_27867_28	SARG|gi|446048013|ref|WP_000125868.1|	28.5	228	513	648	5.49e-23	101
k141_27867_28	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	28.2	245	513	293	5.74e-22	95.1
k141_27867_28	SARG|gi|779852631|ref|WP_045348970.1|	26.8	228	513	646	2.94e-20	93.2
k141_27867_28	SARG|gi|836580371|ref|WP_047737758.1|	26.8	228	513	646	2.94e-20	93.2
k141_27867_28	SARG|gi|798928072|ref|WP_045906664.1|	26.8	228	513	646	2.94e-20	93.2
k141_27867_28	SARG|gi|829942568|ref|WP_047368199.1|	28.1	228	513	646	2.94e-20	93.2
k141_27867_28	SARG|gi|895905590|ref|WP_049005458.1|	26.8	228	513	646	2.94e-20	93.2
k141_27867_28	SARG|gi|746222054|ref|WP_039271209.1|	26.8	228	513	646	2.94e-20	93.2
k141_27867_28	SARG|gi|1022641085|ref|WP_063404331.1|	26.8	228	513	646	2.94e-20	93.2
k141_27867_30	SARG|gb|WP_104671188.1|ARO:3003948|efrA	36.0	547	581	575	2.64e-106	330
k141_27867_30	SARG|gb|AAK76137.1|ARO:3000024|patA	34.8	532	581	564	1.67e-96	304
k141_27867_30	SARG|gb|CDO61516.1|ARO:3003949|efrB	35.5	332	581	362	3.10e-58	197
k141_27867_30	SARG|gi|664170108|ref|WP_030704355.1|	43.6	264	581	603	6.15e-58	203
k141_27867_30	SARG|gi|490068471|ref|WP_003970646.1|	43.6	264	581	603	1.63e-57	202
k141_27867_30	SARG|gi|748767925|ref|WP_040019608.1|	41.5	270	581	623	6.04e-57	201
k141_27867_30	SARG|gi|1045390184|ref|WP_065479071.1|	28.9	529	581	605	6.18e-57	200
k141_27867_30	SARG|gi|501350226|ref|WP_012381861.1|	43.2	264	581	603	8.26e-57	200
k141_27867_30	SARG|gi|953808775|ref|WP_058042812.1|	39.7	282	581	608	8.99e-57	200
k141_27867_30	SARG|gi|943909899|ref|WP_055545300.1|	28.4	529	581	601	1.53e-56	199
k141_27867_31	SARG|gb|AAK76136.1|ARO:3000025|patB	33.5	550	634	588	8.34e-93	297
k141_27867_31	SARG|gb|AYV52072.1|ARO:3002882|lmrD	33.1	532	634	664	1.74e-88	288
k141_27867_31	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	32.6	561	634	578	1.67e-81	267
k141_27867_31	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.8	624	634	579	9.90e-79	259
k141_27867_31	SARG|gb|CDO61516.1|ARO:3003949|efrB	37.3	375	634	362	1.35e-77	250
k141_27867_31	SARG|gi|664180077|ref|WP_030714054.1|	28.9	619	634	605	5.08e-77	256
k141_27867_31	SARG|gi|1033217078|gb|OAR27197.1|	29.9	635	634	601	1.26e-76	254
k141_27867_31	SARG|gi|951183771|ref|WP_057661487.1|	29.0	624	634	603	1.84e-76	254
k141_27867_31	SARG|gi|695865802|ref|WP_032778631.1|	28.8	617	634	605	1.92e-76	254
k141_27867_31	SARG|gi|663330365|ref|WP_030329892.1|	29.6	622	634	607	2.01e-76	254
k141_27867_34	SARG|gi|542061059|gb|ERI11611.1|	32.4	290	293	316	3.19e-36	130
k141_27867_34	SARG|gi|447195835|ref|WP_001273091.1|	33.6	292	293	306	1.03e-34	126
k141_27867_34	SARG|gi|488067981|ref|WP_002139378.1|	33.1	293	293	309	1.54e-34	126
k141_27867_34	SARG|gi|507044560|ref|WP_016115614.1|	31.4	293	293	306	2.02e-34	125
k141_27867_34	SARG|gi|487936534|ref|WP_002010000.1|	32.4	293	293	309	2.15e-34	125
k141_27867_34	SARG|ZP_04081918	32.4	290	293	306	2.82e-34	125
k141_27867_34	SARG|gi|447195836|ref|WP_001273092.1|	33.2	292	293	306	2.82e-34	125
k141_27867_34	SARG|gi|507050365|ref|WP_016121371.1|	32.9	292	293	309	3.01e-34	125
k141_27867_34	SARG|gi|507055561|ref|WP_016126482.1|	32.2	292	293	309	3.01e-34	125
k141_27867_34	SARG|gi|445996708|ref|WP_000074563.1|	32.1	293	293	309	4.20e-34	125
k141_27867_48	SARG|gb|AAV85982.1|ARO:3000535|macB	44.7	38	38	644	3.97e-07	42.4
k141_16572_12	CARD|gb|AAC75429.1|ARO:3000833|evgS	30.6	111	301	1197	6.64e-07	49.7
k141_6697_2	NCBI|WP_011860980.1|1|1|blaAHM-1|blaAHM|hydrolase|2|CARBAPENEM|beta-lactam|subclass_B3-like_metallo-beta-lactamase_AHM-1|AMR|beta-lactam	29.4	228	287	304	4.33e-35	127
k141_6697_21	SARG|CAA37477	43.6	140	615	663	1.66e-28	119
k141_6697_21	SARG|YP_002850805	25.4	452	615	652	8.92e-28	117
k141_6697_21	SARG|NP_348076	25.6	446	615	652	2.81e-27	115
k141_6697_21	SARG|ZP_02952732	25.7	447	615	652	3.74e-27	115
k141_6697_21	SARG|ZP_02632674	25.7	447	615	660	3.83e-27	115
k141_6697_21	SARG|L20800.gene.p01	26.8	351	615	652	1.56e-26	113
k141_6697_21	SARG|ABN79417	43.8	128	615	639	1.90e-24	107
k141_6697_21	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	43.0	128	615	629	5.74e-24	105
k141_6697_21	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	43.0	128	615	629	5.74e-24	105
k141_6697_21	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	43.0	128	615	629	5.74e-24	105
k141_6697_28	SARG|GQ205627.2.gene3.p01	39.0	118	215	216	1.24e-14	68.9
k141_6697_28	SARG|U19459.gene.p01	51.0	51	215	212	2.18e-13	65.5
k141_6697_28	SARG|AF139725.gene.p01	33.9	112	215	214	3.10e-13	65.1
k141_6697_28	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	33.9	112	215	214	3.10e-13	65.1
k141_6697_28	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	33.9	112	215	214	3.10e-13	65.1
k141_6697_28	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	33.9	112	215	214	3.10e-13	65.1
k141_6697_28	NCBI|WP_063856934.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	33.9	112	215	214	3.10e-13	65.1
k141_6697_28	SARG|AAK91782	33.9	112	215	214	3.10e-13	65.1
k141_6697_28	SARG|AAG21695	33.9	112	215	214	4.28e-13	64.7
k141_6697_28	SARG|AAF24171	33.0	112	215	214	5.91e-13	64.3
k141_62429_7	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	49.2	189	182	703	4.01e-52	176
k141_252299_3	SARG|gi|1035706844|ref|WP_064548272.1|	32.7	110	966	648	2.16e-08	57.0
k141_128419_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	40.3	176	209	219	4.76e-39	132
k141_128419_1	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.3	209	209	232	1.89e-38	131
k141_128419_1	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.3	209	209	232	1.89e-38	131
k141_128419_1	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.7	181	209	231	2.27e-36	126
k141_128419_1	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.8	183	209	232	4.63e-36	125
k141_128419_1	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.0	182	209	231	1.78e-35	124
k141_128419_1	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.5	182	209	231	1.78e-35	124
k141_128419_1	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.5	182	209	231	7.02e-35	122
k141_128419_1	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.5	182	209	231	7.02e-35	122
k141_128419_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	40.0	175	209	228	2.57e-34	120
k141_128419_2	SARG|DQ212986.1.gene3.p01	42.9	63	76	75	3.82e-13	57.4
k141_128419_6	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.9	328	421	381	9.42e-14	71.2
k141_128419_6	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	22.9	328	421	381	9.42e-14	71.2
k141_128419_6	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.2	328	421	381	1.26e-13	70.9
k141_128419_6	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.2	328	421	381	1.26e-13	70.9
k141_128419_6	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	23.5	247	421	370	2.12e-13	70.1
k141_128419_6	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	21.0	319	421	381	2.25e-13	70.1
k141_128419_6	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	21.0	319	421	381	2.25e-13	70.1
k141_128419_6	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	23.2	311	421	381	1.27e-12	67.8
k141_128419_6	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	23.2	311	421	381	1.27e-12	67.8
k141_128419_6	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	22.1	298	421	381	7.19e-12	65.5
k141_128419_7	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	44.1	222	227	255	8.03e-65	200
k141_128419_7	SARG|gi|896325272|ref|WP_049294291.1|	46.4	222	227	648	2.91e-56	188
k141_128419_7	SARG|gi|639225329|ref|WP_024561799.1|	46.6	223	227	648	5.64e-56	187
k141_128419_7	SARG|gi|639218559|ref|WP_024556062.1|	46.6	223	227	648	5.64e-56	187
k141_128419_7	SARG|gi|657888313|ref|WP_029592374.1|	45.5	222	227	648	7.85e-56	187
k141_128419_7	SARG|gi|639216333|ref|WP_024554080.1|	45.9	222	227	648	7.85e-56	187
k141_128419_7	SARG|gi|498115003|ref|WP_010429159.1|	46.2	223	227	646	2.87e-55	185
k141_128419_7	SARG|gi|974588181|ref|WP_059178476.1|	46.2	223	227	646	5.56e-55	184
k141_128419_7	SARG|gi|782756348|ref|WP_045630015.1|	46.2	223	227	646	5.56e-55	184
k141_128419_7	SARG|gi|746253210|ref|WP_039301529.1|	45.5	222	227	648	5.71e-55	184
k141_173754_11	SARG|gb|CAE00499.1|ARO:3003835|cdeA	22.4	419	444	441	1.17e-20	92.8
k141_173754_11	SARG|gi|505177635|ref|WP_015364737.1|	21.9	433	444	451	2.36e-19	89.0
k141_173754_11	SARG|YP_302230	22.5	378	444	451	4.38e-18	85.1
k141_173754_11	SARG|HE999704.1.gene3064.p01	22.7	203	444	241	1.89e-12	65.9
k141_173754_11	SARG|gi|441475675|emb|CCQ25429.1|	27.4	113	444	211	6.88e-10	57.8
k141_173754_18	NCBI|XSG12257.1|1|1|drcB|drcB||1|||daptomycin_efflux_ABC_transporter_permease_DrcB|AMR|peptide	33.0	115	355	641	1.30e-12	67.8
k141_128456_6	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.6	222	232	219	8.54e-37	127
k141_128456_6	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.6	219	232	219	2.39e-36	126
k141_128456_6	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.6	219	232	220	2.45e-36	126
k141_128456_6	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.1	222	232	220	2.45e-36	126
k141_128456_6	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.6	219	232	220	3.46e-36	126
k141_128456_6	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.0	219	232	228	1.68e-35	124
k141_128456_6	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	31.5	232	232	230	2.97e-33	119
k141_128456_6	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.0	228	232	231	2.36e-32	116
k141_128456_6	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	31.1	228	232	231	1.97e-30	111
k141_128456_6	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	32.7	220	232	223	6.35e-30	110
k141_28753_4	CARD|gb|BAB36671.1|ARO:3000832|evgA	22.7	207	218	204	2.91e-14	67.8
k141_28753_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	26.8	112	218	228	6.43e-11	58.9
k141_28753_4	CARD|gb|ADM92605.1|ARO:3000553|adeR	20.8	216	218	247	4.25e-07	48.1
k141_28753_4	CARD|gb|AAD51348.1|ARO:3003066|smeR	24.3	115	218	229	1.75e-06	46.2
k141_28753_4	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	27.4	84	218	232	3.25e-06	45.4
k141_28753_4	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	27.4	84	218	232	5.94e-06	44.7
k141_28753_4	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	27.4	84	218	232	5.94e-06	44.7
k141_28753_4	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	27.4	84	218	232	5.94e-06	44.7
k141_28753_4	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	27.4	84	218	232	5.94e-06	44.7
k141_28753_6	SARG|gi|445996710|ref|WP_000074565.1|	31.3	227	510	309	2.64e-13	69.7
k141_28753_6	SARG|gi|447195835|ref|WP_001273091.1|	32.7	211	510	306	1.49e-12	67.4
k141_28753_6	SARG|gi|447195836|ref|WP_001273092.1|	32.7	211	510	306	1.49e-12	67.4
k141_28753_6	SARG|gi|542061059|gb|ERI11611.1|	32.4	213	510	316	1.63e-12	67.4
k141_28753_6	SARG|P42332	31.4	210	510	306	2.00e-12	67.0
k141_28753_6	SARG|ABB80128	31.4	210	510	306	2.00e-12	67.0
k141_28753_6	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	31.4	210	510	306	2.00e-12	67.0
k141_28753_6	SARG|gi|895736250|emb|COF64653.1|	30.8	227	510	309	2.06e-12	67.0
k141_28753_6	SARG|gi|446110087|ref|WP_000187942.1|	30.8	227	510	309	2.06e-12	67.0
k141_28753_6	SARG|gi|510143239|gb|AGN36970.1|	31.4	210	510	313	2.13e-12	67.0
k141_28753_11	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	40.0	105	458	533	1.61e-10	62.0
k141_28753_11	SARG|AF353562.gene.p01	40.0	105	458	369	3.37e-10	60.5
k141_28753_12	SARG|gb|WP_021361759.1|ARO:3006905|CDD-2	41.4	251	345	308	2.39e-63	202
k141_28753_12	SARG|gb|WP_009901927.1|ARO:3006904|CDD-1	40.6	251	345	312	4.65e-61	197
k141_28753_12	SARG|AAK14791	27.8	223	345	260	1.33e-23	97.1
k141_28753_12	SARG|Q00983	27.4	223	345	260	6.68e-23	95.1
k141_28753_12	NCBI|WP_213994604.1|1|1|blaOXA-965|blaOXA-55_fam|hydrolase|2|beta-lactam|beta-lactam|OXA-55_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-965|AMR|beta-lactam	28.1	224	345	289	4.66e-20	87.8
k141_28753_12	SARG|gb|WP_114699266.1|ARO:3005934|OXA-729	28.1	224	345	289	6.39e-20	87.4
k141_28753_12	NCBI|WP_213994602.1|1|1|blaOXA-961|blaOXA-55_fam|hydrolase|2|beta-lactam|beta-lactam|OXA-55_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-961|AMR|beta-lactam	26.9	227	345	289	8.75e-20	87.0
k141_28753_12	NCBI|WP_025889747.1|1|1|blaOXA-964|blaOXA-55_fam|hydrolase|2|beta-lactam|beta-lactam|OXA-55_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-964|AMR|beta-lactam	28.1	224	345	289	8.75e-20	87.0
k141_28753_12	SARG|AY343493.1.gene1.p01	27.7	224	345	289	1.64e-19	86.3
k141_28753_12	NCBI|WP_213994603.1|1|1|blaOXA-963|blaOXA-55_fam|hydrolase|2|beta-lactam|beta-lactam|OXA-55_family_carbapenem-hydrolyzing_class_D_beta-lactamase_OXA-963|AMR|beta-lactam	28.1	224	345	289	2.25e-19	85.9
k141_28753_15	NCBI|WP_001255868.1|1|1|aadE|aadE|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_6-adenylyltransferase_AadE|AMR|aminoglycoside	80.1	281	285	288	3.91e-174	481
k141_28753_15	SARG|FN594949.1.gene25.p01	73.0	281	285	285	6.94e-158	440
k141_28753_15	NCBI|WP_001255864.1|1|1|ant(6)-Ia|ant(6)-Ia|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia|AMR|aminoglycoside	65.1	281	285	302	4.66e-139	393
k141_28753_15	NCBI|WP_001255866.1|1|1|ant(6)-Ia|ant(6)-Ia|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia|AMR|aminoglycoside	64.1	281	285	302	2.08e-135	384
k141_28753_15	NCBI|WP_032491779.1|1|1|ant(6)-Ia|ant(6)-Ia|nucleotidyltransferase|2|STREPTOMYCIN|aminoglycoside|aminoglycoside_nucleotidyltransferase_ANT(6)-Ia|AMR|aminoglycoside	63.7	281	285	302	2.80e-133	378
k141_28753_15	SARG|JQ861959.1.gene5.p01	61.1	283	285	287	4.25e-129	367
k141_28753_15	SARG|NC_006663.1.orf0.gene.p01	64.3	258	285	279	2.89e-125	357
k141_28753_15	SARG|AY712687.1.gene1.p01	64.3	255	285	276	8.61e-124	353
k141_28753_15	SARG|gi|1039476118|ref|WP_064814315.1|	58.2	275	285	284	3.16e-116	334
k141_28753_15	SARG|gi|504290343|ref|WP_014477445.1|	58.5	275	285	284	4.49e-116	334
k141_197253_17	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	36.6	186	203	255	2.92e-34	121
k141_197253_17	SARG|gi|502669352|ref|WP_012905216.1|	39.2	186	203	648	1.10e-31	119
k141_197253_17	SARG|gi|803568669|ref|WP_046077412.1|	38.7	186	203	648	3.85e-31	118
k141_197253_17	SARG|gi|446110352|ref|WP_000188207.1|	38.7	186	203	648	3.85e-31	118
k141_197253_17	SARG|YP_002382193	38.7	186	203	648	3.85e-31	118
k141_197253_17	SARG|gi|803575554|ref|WP_046081557.1|	38.7	186	203	648	3.85e-31	118
k141_197253_17	SARG|gi|446110351|ref|WP_000188206.1|	38.7	186	203	648	3.85e-31	118
k141_197253_17	SARG|gi|736472622|ref|WP_034494292.1|	38.2	186	203	648	2.64e-28	110
k141_197253_17	SARG|gi|1035706844|ref|WP_064548272.1|	38.2	186	203	648	4.90e-28	109
k141_197253_17	SARG|gi|1035670474|ref|WP_064517458.1|	37.6	186	203	648	9.10e-28	108
k141_85454_8	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	24.6	621	584	633	3.34e-32	130
k141_85454_33	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	39.8	231	227	232	1.67e-53	171
k141_85454_33	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.6	230	227	231	1.30e-52	168
k141_85454_33	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.2	220	227	220	5.31e-52	166
k141_85454_33	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.2	220	227	219	7.30e-52	166
k141_85454_33	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.2	220	227	220	7.52e-52	166
k141_85454_33	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.6	220	227	220	7.52e-52	166
k141_85454_33	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	38.8	227	227	230	1.01e-51	166
k141_85454_33	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	37.7	220	227	219	5.85e-51	164
k141_85454_33	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	39.0	228	227	231	1.88e-49	160
k141_85454_33	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.0	228	227	231	1.88e-49	160
k141_85454_36	NCBI|AAN33535.1|1|1|bepF|bepF|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_periplasmic_adaptor_subunit_BepF|AMR|efflux	26.0	196	602	411	1.37e-08	56.2
k141_85454_37	SARG|YP_001186705	26.1	1008	1046	1017	2.27e-83	291
k141_85454_37	CARD|gb|AAC75136.1|ARO:3000793|mdtB	23.9	1012	1046	1040	1.76e-77	274
k141_85454_37	SARG|YP_001266290	25.3	1019	1046	1014	8.24e-77	272
k141_85454_37	SARG|YP_001670703	25.0	1016	1046	1014	2.80e-76	270
k141_85454_37	SARG|CAY51926	24.5	1015	1046	1008	8.91e-76	269
k141_85454_37	CARD|gb|AAC75137.1|ARO:3000794|mdtC	24.7	1004	1046	1025	1.08e-75	269
k141_85454_37	SARG|YP_350221	24.8	1006	1046	1009	2.59e-74	265
k141_85454_37	SARG|YP_606823	24.4	1013	1046	1011	1.01e-72	260
k141_85454_37	SARG|YP_792720	25.1	1008	1046	1018	1.47e-72	259
k141_85454_37	SARG|AAG07763	25.1	1008	1046	1018	1.47e-72	259
k141_85454_38	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.0	204	488	392	3.33e-24	103
k141_85454_38	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.4	239	488	364	1.08e-23	101
k141_85454_38	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.4	239	488	364	1.08e-23	101
k141_85454_38	CARD|gb|ABD30512.1|ARO:3000839|arlS	25.2	329	488	451	1.56e-22	99.0
k141_85454_38	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.5	314	488	447	2.03e-22	98.6
k141_85454_38	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.5	314	488	447	2.03e-22	98.6
k141_85454_38	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.5	314	488	447	2.03e-22	98.6
k141_85454_38	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.4	311	488	447	3.67e-22	97.8
k141_85454_38	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	24.5	314	488	454	1.76e-20	92.8
k141_85454_38	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.6	199	488	359	6.32e-20	90.1
k141_52020_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	28.0	125	299	228	1.88e-06	47.0
k141_52020_8	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.6	221	222	255	5.88e-58	182
k141_52020_8	SARG|Q83LR7	42.7	220	222	648	1.81e-51	175
k141_52020_8	SARG|gi|647325472|ref|WP_025760953.1|	42.7	220	222	648	1.81e-51	175
k141_52020_8	SARG|gi|647323678|ref|WP_025760497.1|	42.7	220	222	648	1.81e-51	175
k141_52020_8	SARG|gi|742378414|ref|WP_038857601.1|	42.5	221	222	647	6.67e-51	173
k141_52020_8	SARG|gi|495736522|ref|WP_008461101.1|	42.5	221	222	648	6.74e-51	173
k141_52020_8	SARG|gi|746253210|ref|WP_039301529.1|	42.5	221	222	648	6.74e-51	173
k141_52020_8	SARG|gi|446110305|ref|WP_000188160.1|	42.3	220	222	648	6.74e-51	173
k141_52020_8	SARG|gi|823326845|ref|WP_047080664.1|	42.3	220	222	648	9.36e-51	173
k141_52020_8	SARG|gi|746243059|ref|WP_039291473.1|	43.0	221	222	648	9.36e-51	173
k141_52020_10	SARG|HE999704.1.gene3064.p01	27.8	237	459	241	9.36e-19	84.3
k141_52020_10	SARG|gi|441475675|emb|CCQ25429.1|	28.2	174	459	211	6.47e-11	60.8
k141_52020_11	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	41.9	234	229	255	9.64e-56	177
k141_52020_11	SARG|gi|754927849|ref|WP_042284850.1|	44.4	223	229	648	1.19e-54	184
k141_52020_11	SARG|gi|835330218|ref|WP_047457825.1|	43.5	230	229	648	1.65e-54	183
k141_52020_11	SARG|YP_001453760	43.5	230	229	648	1.65e-54	183
k141_52020_11	SARG|gi|639225329|ref|WP_024561799.1|	42.6	230	229	648	6.18e-54	182
k141_52020_11	SARG|gi|763399392|ref|WP_044256358.1|	43.5	223	229	648	6.18e-54	182
k141_52020_11	SARG|gi|639218559|ref|WP_024556062.1|	42.6	230	229	648	6.18e-54	182
k141_52020_11	SARG|gi|657888313|ref|WP_029592374.1|	42.2	230	229	648	8.59e-54	181
k141_52020_11	SARG|gi|949718947|ref|WP_057063453.1|	43.0	230	229	648	8.59e-54	181
k141_52020_11	SARG|gi|896325272|ref|WP_049294291.1|	43.3	224	229	648	8.59e-54	181
k141_52020_12	megares|MEG_7331|Drugs|Glycopeptide|VanA-type_resistance_protein|VAN_1	60.5	38	849	114	1.44e-09	55.5
k141_52020_12	CARD|gb|AAO82019.1|ARO:3004254|vanV_in_vanB_cl	60.5	38	849	114	1.44e-09	55.5
k141_52020_21	CARD|gb|BAE77778.1|ARO:3000508|gadX	23.7	224	521	274	2.49e-07	51.2
k141_52020_31	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.8	829	918	1024	7.05e-61	223
k141_52020_31	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.8	829	918	1024	7.05e-61	223
k141_52020_31	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.8	829	918	1024	2.30e-60	222
k141_52020_31	SARG|gb|CAA53189|ARO:3000521|mupA	23.8	829	918	1024	2.30e-60	222
k141_52020_44	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.3	403	861	1197	7.59e-41	161
k141_52020_44	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.1	236	861	364	2.87e-14	74.3
k141_52020_44	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.1	236	861	364	2.87e-14	74.3
k141_52020_44	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	22.5	236	861	359	2.76e-12	68.2
k141_52020_44	SARG|ZP_02848503	29.8	124	861	221	1.62e-07	52.0
k141_52020_47	SARG|NP_348076	30.3	656	959	652	1.00e-84	285
k141_52020_47	SARG|AAV80410	30.4	664	959	651	9.51e-84	282
k141_52020_47	SARG|YP_002850805	29.6	653	959	652	9.74e-84	282
k141_52020_47	SARG|L42544.gene.p01	29.5	664	959	651	3.48e-83	281
k141_52020_47	SARG|ZP_02952732	29.5	651	959	652	6.82e-83	280
k141_52020_47	SARG|ZP_02632674	29.5	651	959	660	8.18e-83	280
k141_52020_47	SARG|L20800.gene.p01	29.3	651	959	652	2.49e-82	278
k141_52020_47	SARG|AJ514254.gene.p01	29.4	646	959	640	5.00e-82	277
k141_52020_47	SARG|Q00937	28.2	642	959	641	2.05e-76	262
k141_52020_47	SARG|ZP_04557016	28.2	642	959	657	2.90e-76	262
k141_52020_52	SARG|gi|505177635|ref|WP_015364737.1|	32.5	440	464	451	1.39e-66	219
k141_52020_52	SARG|gi|488374619|ref|WP_002444004.1|	32.7	441	464	452	1.52e-65	216
k141_52020_52	SARG|ZP_04679156	31.8	440	464	451	2.20e-64	213
k141_52020_52	SARG|gi|984518628|emb|CUM21384.1|	31.0	316	464	341	3.68e-45	159
k141_52020_52	SARG|HE999704.1.gene1126.p01	26.1	322	464	337	3.09e-34	130
k141_52020_52	SARG|gi|441473784|emb|CCQ23538.1|	26.1	322	464	336	1.99e-32	125
k141_52020_76	SARG|gb|WP_104671188.1|ARO:3003948|efrA	34.4	572	606	575	8.25e-109	337
k141_52020_76	SARG|gb|AAK76137.1|ARO:3000024|patA	31.9	558	606	564	1.52e-88	284
k141_52020_76	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	30.0	496	606	579	8.10e-55	194
k141_52020_76	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.9	495	606	579	8.10e-55	194
k141_52020_76	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	27.6	609	606	579	1.47e-53	191
k141_52020_76	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.3	612	606	579	2.03e-53	191
k141_52020_76	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	28.9	408	606	574	1.67e-51	185
k141_52020_76	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.9	524	606	664	1.59e-50	184
k141_52020_76	SARG|gb|AAK76136.1|ARO:3000025|patB	24.6	570	606	588	9.60e-50	181
k141_52020_76	SARG|gi|928900436|ref|WP_053931243.1|	39.2	240	606	600	9.63e-48	175
k141_52020_77	SARG|gb|AAK76136.1|ARO:3000025|patB	32.8	585	589	588	1.03e-104	327
k141_52020_77	SARG|gb|AYV52072.1|ARO:3002882|lmrD	35.4	517	589	664	1.45e-99	315
k141_52020_77	SARG|gb|CDO61516.1|ARO:3003949|efrB	43.7	323	589	362	1.23e-86	272
k141_52020_77	SARG|gi|928900436|ref|WP_053931243.1|	30.0	586	589	600	6.28e-83	270
k141_52020_77	SARG|gi|664579989|ref|WP_031094015.1|	30.0	586	589	601	6.43e-83	270
k141_52020_77	SARG|gi|944009777|ref|WP_055601444.1|	31.1	586	589	628	1.21e-82	270
k141_52020_77	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.0	575	589	579	1.46e-82	268
k141_52020_77	SARG|gi|1045390184|ref|WP_065479071.1|	29.8	581	589	605	1.94e-82	269
k141_52020_77	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.4	579	589	579	2.86e-82	268
k141_52020_77	SARG|gi|663155409|ref|WP_030194633.1|	29.6	584	589	605	1.45e-81	266
k141_52020_81	CARD|gb|AEX49906.1|ARO:3003583|basS	29.7	219	557	477	9.17e-19	88.2
k141_52020_81	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	23.6	246	557	364	2.51e-16	79.7
k141_52020_81	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	23.6	246	557	364	2.51e-16	79.7
k141_52020_81	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	21.1	242	557	359	3.43e-13	70.1
k141_52020_81	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	109	557	219	5.09e-08	52.8
k141_52020_81	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	109	557	219	5.09e-08	52.8
k141_52020_81	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	109	557	220	5.15e-08	52.8
k141_52020_81	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	33.9	109	557	220	6.93e-08	52.4
k141_52020_81	SARG|ZP_02848503	31.5	108	557	221	1.01e-06	48.9
k141_52020_81	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	32.1	109	557	220	1.81e-06	48.1
k141_52020_92	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	30.4	230	323	255	6.19e-26	102
k141_52020_92	SARG|gi|505180394|ref|WP_015367496.1|	31.8	233	323	648	2.22e-22	96.7
k141_52020_92	SARG|gi|823302270|ref|WP_047057473.1|	31.8	233	323	648	4.04e-22	95.9
k141_52020_92	SARG|gi|976146774|ref|WP_059305359.1|	31.8	233	323	648	4.04e-22	95.9
k141_52020_92	SARG|gi|1022664304|ref|WP_063420886.1|	31.8	233	323	648	4.04e-22	95.9
k141_52020_92	SARG|gi|823309640|ref|WP_047064288.1|	31.8	233	323	648	4.04e-22	95.9
k141_52020_92	SARG|gi|505807117|ref|WP_015704872.1|	31.8	233	323	648	4.04e-22	95.9
k141_52020_92	SARG|gi|518923394|ref|WP_020079269.1|	31.8	233	323	648	4.04e-22	95.9
k141_52020_92	SARG|gi|695797094|ref|WP_032711285.1|	31.8	233	323	648	4.04e-22	95.9
k141_52020_92	SARG|gi|823299155|ref|WP_047054544.1|	31.8	233	323	648	4.04e-22	95.9
k141_52020_109	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	37.4	230	245	225	5.06e-44	147
k141_52020_109	CARD|gb|AAC73788.1|ARO:3003841|kdpE	37.0	230	245	225	1.42e-43	145
k141_52020_109	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.8	231	245	231	2.55e-39	135
k141_52020_109	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	35.1	231	245	231	5.07e-39	134
k141_52020_109	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.1	231	245	231	5.07e-39	134
k141_52020_109	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.6	231	245	231	2.00e-38	132
k141_52020_109	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.2	231	245	231	5.59e-38	131
k141_52020_109	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	33.9	227	245	229	1.48e-37	130
k141_52020_109	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.8	238	245	235	2.08e-35	125
k141_52020_109	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	31.3	227	245	223	3.32e-34	121
k141_52020_110	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.2	246	413	381	3.27e-17	81.6
k141_52020_110	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.2	246	413	381	3.27e-17	81.6
k141_52020_110	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.2	246	413	381	4.66e-16	78.2
k141_52020_110	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.2	246	413	381	4.66e-16	78.2
k141_52020_111	SARG|gi|555258323|ref|WP_023240896.1|	44.1	220	227	648	5.79e-53	179
k141_52020_111	SARG|gi|922960663|ref|WP_053388845.1|	43.6	220	227	648	5.79e-53	179
k141_52020_111	SARG|gi|555222481|ref|WP_023215070.1|	44.5	220	227	648	5.79e-53	179
k141_52020_111	SARG|gi|757799695|ref|WP_043016897.1|	43.6	220	227	648	8.05e-53	179
k141_52020_111	SARG|gi|1045891604|ref|WP_065554100.1|	43.6	220	227	648	8.05e-53	179
k141_52020_111	SARG|gi|507082903|ref|WP_016153652.1|	43.6	220	227	648	8.05e-53	179
k141_52020_111	SARG|gi|740856590|ref|WP_038641842.1|	43.6	220	227	648	8.05e-53	179
k141_52020_111	SARG|gi|959866458|ref|WP_058145168.1|	44.1	220	227	648	8.05e-53	179
k141_52020_111	SARG|gi|554685678|ref|WP_023185565.1|	44.1	220	227	648	8.05e-53	179
k141_52020_111	SARG|gi|555246906|ref|WP_023230855.1|	44.1	220	227	648	1.12e-52	178
k141_221390_23	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.9	116	121	228	3.35e-16	70.5
k141_221390_23	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.3	113	121	204	2.56e-14	65.1
k141_221390_23	CARD|gb|AAD51348.1|ARO:3003066|smeR	29.1	117	121	229	5.02e-12	59.3
k141_221390_23	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	30.1	103	121	225	1.29e-11	58.2
k141_221390_23	CARD|gb|AAC73788.1|ARO:3003841|kdpE	30.1	103	121	225	1.29e-11	58.2
k141_221390_23	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.2	106	121	1197	4.04e-09	52.0
k141_221390_49	SARG|gi|1004359922|gb|AMP42228.1|	26.9	453	605	639	7.87e-30	123
k141_221390_49	SARG|ABV82118	23.8	454	605	639	4.47e-29	121
k141_221390_49	SARG|ABV82120	24.0	454	605	639	5.97e-29	120
k141_221390_49	SARG|ZP_03989103	23.8	454	605	639	1.89e-28	119
k141_221390_49	SARG|AAY62597	26.9	454	605	639	3.37e-28	118
k141_221390_49	SARG|gi|168258996|gb|ACA23181.1|	26.9	454	605	639	4.49e-28	118
k141_221390_49	SARG|ACA23195	26.9	454	605	639	4.49e-28	118
k141_221390_49	SARG|gi|254967129|gb|ACT97610.1|	26.9	454	605	639	5.99e-28	117
k141_221390_49	SARG|gb|AMP42147.1|ARO:3004442|tet(W/N/W)	26.7	454	605	639	5.99e-28	117
k141_221390_49	SARG|AJ222769.gene.p01	26.9	454	605	639	5.99e-28	117
k141_221390_61	SARG|YP_002861121	45.6	57	210	212	1.90e-12	62.8
k141_221390_61	SARG|YP_001779894	49.2	59	210	212	1.80e-11	60.1
k141_221390_61	SARG|YP_001389621	47.5	59	210	212	4.69e-11	58.9
k141_221390_61	SARG|YP_001785579	47.5	59	210	212	8.88e-11	58.2
k141_221390_61	SARG|U19459.gene.p01	38.6	70	210	212	1.12e-09	55.1
k141_221390_61	NCBI|WP_031281281.1|1|1|catB|catB|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B_phenicol_O-acetyltransferase|AMR|phenicol	26.4	129	210	210	2.06e-09	54.3
k141_221390_61	NCBI|WP_021018581.1|1|1|catB8|catB8|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB8|AMR|phenicol	28.0	125	210	210	2.82e-09	53.9
k141_221390_61	NCBI|WP_071846375.1|1|1|catB3|catB3|acetyltransferase|2|CHLORAMPHENICOL|PHENICOL|type_B-3_phenicol_O-acetyltransferase_CatB3|AMR|phenicol	28.6	126	210	210	2.82e-09	53.9
k141_221390_61	SARG|M58472.1.gene1.p01	28.0	118	210	209	3.82e-09	53.5
k141_221390_61	SARG|ABF20240	28.6	126	210	210	5.28e-09	53.1
k141_187112_2	SARG|gi|500194536|ref|WP_011867743.1|	40.8	233	340	306	1.88e-49	166
k141_187112_2	SARG|YP_001373621	36.2	312	340	318	2.57e-49	166
k141_187112_2	SARG|gi|488053456|ref|WP_002124853.1|	35.4	311	340	309	4.02e-49	166
k141_187112_2	SARG|gi|445996710|ref|WP_000074565.1|	36.2	312	340	309	5.66e-49	165
k141_187112_2	SARG|P42332	34.7	311	340	306	7.35e-49	165
k141_187112_2	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	34.7	311	340	306	7.35e-49	165
k141_187112_2	SARG|gi|488067981|ref|WP_002139378.1|	35.4	311	340	309	7.95e-49	165
k141_187112_2	SARG|gi|487936534|ref|WP_002010000.1|	35.4	311	340	309	7.95e-49	165
k141_187112_2	SARG|gi|510143239|gb|AGN36970.1|	34.7	311	340	313	8.81e-49	165
k141_187112_2	SARG|gi|488068784|ref|WP_002140181.1|	35.6	312	340	309	1.57e-48	164
k141_187112_26	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	24.6	451	449	633	1.28e-21	96.7
k141_187112_49	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	29.4	333	960	633	3.70e-29	123
k141_187112_49	SARG|gb|AQX82857.1|ARO:3004185|mecD	22.6	350	960	678	3.22e-09	59.7
k141_187112_49	SARG|gb|BAI83385.1|ARO:3003440|mecB	32.8	134	960	674	1.48e-07	54.3
k141_187112_49	megares|MEG_3799|Drugs|beta-lactam|Penicillin_binding_protein|MECC_1	23.7	334	960	664	1.93e-07	53.9
k141_187112_49	NCBI|WP_063852710.1|1|1|mecB|mecB|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecB|AMR|beta-lactam	32.8	134	960	674	2.56e-07	53.5
k141_187112_49	SARG|gb|CCC86795.1|ARO:3001209|mecC	23.8	336	960	665	4.40e-07	52.8
k141_187112_49	megares|MEG_3792|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	35.7	129	960	666	4.40e-07	52.8
k141_187112_49	NCBI|WP_128268231.1|1|1|mecC2|mecC2|insensitivity|2|METHICILLIN|beta-lactam|PBP2a_family_beta-lactam-resistant_peptidoglycan_transpeptidase_MecC2|AMR|beta-lactam	23.2	336	960	665	1.31e-06	51.2
k141_187112_49	SARG|gi|2791908|emb|CAA73538.1|	34.6	127	960	666	1.73e-06	50.8
k141_187112_49	megares|MEG_3789|Drugs|beta-lactam|Penicillin_binding_protein|MECA_1	25.6	332	960	668	2.99e-06	50.1
k141_187112_55	NCBI|WP_063856854.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.8	260	330	356	3.15e-27	108
k141_187112_55	NCBI|WP_063856862.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.8	260	330	356	1.15e-26	107
k141_187112_55	NCBI|WP_049898469.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	30.4	260	330	356	3.01e-26	105
k141_187112_111	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	38.7	687	643	703	8.16e-137	415
k141_187112_112	SARG|gb|AAG05187.1|ARO:3005067|ParS	25.0	220	736	428	7.05e-11	63.9
k141_187112_112	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.8	120	736	220	1.78e-07	51.6
k141_187112_112	CARD|gb|ATC67679.1|ARO:3000838|arlR	31.4	118	736	219	4.29e-07	50.4
k141_187112_112	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.0	120	736	220	4.34e-07	50.4
k141_187112_112	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.0	120	736	219	1.04e-06	49.3
k141_187112_112	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.0	120	736	219	1.04e-06	49.3
k141_187112_112	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	30.0	120	736	220	1.05e-06	49.3
k141_187112_133	SARG|gb|AAV85982.1|ARO:3000535|macB	30.3	234	318	644	4.02e-21	92.8
k141_187112_133	SARG|gi|896106549|ref|WP_049136608.1|	29.6	226	318	646	3.25e-20	90.1
k141_187112_133	SARG|gi|896325272|ref|WP_049294291.1|	28.8	250	318	648	3.26e-20	90.1
k141_187112_133	SARG|gi|654544841|ref|WP_028012549.1|	29.2	226	318	646	4.38e-20	89.7
k141_187112_133	SARG|gi|983405167|ref|WP_060572706.1|	29.0	255	318	646	7.96e-20	89.0
k141_187112_133	SARG|gi|639225329|ref|WP_024561799.1|	29.2	250	318	648	7.97e-20	89.0
k141_187112_133	SARG|gi|639218559|ref|WP_024556062.1|	29.2	250	318	648	7.97e-20	89.0
k141_187112_133	SARG|gi|740633514|ref|WP_038419019.1|	29.0	255	318	646	1.07e-19	88.6
k141_187112_133	SARG|gi|782756348|ref|WP_045630015.1|	29.4	255	318	646	1.07e-19	88.6
k141_187112_133	SARG|gi|498115003|ref|WP_010429159.1|	29.0	255	318	646	1.07e-19	88.6
k141_187112_134	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	31.8	233	327	255	6.61e-28	108
k141_187112_134	SARG|gi|694102529|ref|WP_032445810.1|	30.5	236	327	646	2.10e-20	90.9
k141_187112_134	SARG|gi|644804533|ref|WP_025368306.1|	29.6	243	327	646	2.82e-20	90.5
k141_187112_134	SARG|gi|1044231927|emb|SBX14918.1|	29.6	243	327	646	2.82e-20	90.5
k141_187112_134	SARG|gi|960851665|ref|WP_058330789.1|	29.6	243	327	646	2.82e-20	90.5
k141_187112_134	SARG|gi|490249706|ref|WP_004147781.1|	29.6	243	327	646	2.82e-20	90.5
k141_187112_134	SARG|gi|556436452|ref|WP_023312896.1|	29.6	243	327	646	2.82e-20	90.5
k141_187112_134	SARG|gi|1044175355|emb|SBY84545.1|	29.6	243	327	646	2.82e-20	90.5
k141_187112_134	SARG|gi|896074949|ref|WP_049117877.1|	29.6	243	327	646	2.82e-20	90.5
k141_187112_134	SARG|gi|823326845|ref|WP_047080664.1|	29.9	234	327	648	2.83e-20	90.5
k141_187112_173	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	50.9	159	160	159	3.05e-53	165
k141_41985_2	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	29.5	207	1141	722	2.21e-18	89.7
k141_109963_5	SARG|gb|ABA71729.1|ARO:3002959|vanYG1	75.0	176	251	279	2.32e-96	282
k141_109963_5	SARG|AAF71279	68.2	176	251	278	1.97e-82	247
k141_109963_5	SARG|gi|403023847|gb|EJY36064.1|	55.0	180	251	200	1.54e-63	196
k141_109963_5	SARG|gi|452996213|gb|AGG19398.1|	51.2	207	251	268	2.22e-63	198
k141_109963_5	SARG|gi|498515090|ref|WP_010815297.1|	51.2	207	251	268	2.22e-63	198
k141_109963_5	SARG|gi|452996227|gb|AGG19410.1|	55.0	180	251	252	7.77e-63	196
k141_109963_5	SARG|Q47746	50.7	207	251	268	8.89e-63	196
k141_109963_5	SARG|gi|488259314|ref|WP_002330522.1|	55.0	180	251	268	1.26e-62	196
k141_109963_5	SARG|gi|1036536100|emb|SAM71699.1|	55.0	180	251	268	1.26e-62	196
k141_109963_5	SARG|gi|403219412|emb|CCJ27774.1|	55.0	180	251	268	1.26e-62	196
k141_109963_6	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	49.5	372	377	386	1.30e-108	322
k141_109963_6	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	49.5	372	377	386	1.30e-108	322
k141_109963_6	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	48.1	370	377	382	1.05e-106	317
k141_109963_6	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	48.1	370	377	382	1.05e-106	317
k141_109963_6	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	48.4	372	377	386	2.39e-106	317
k141_109963_6	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	48.4	372	377	386	2.39e-106	317
k141_109963_6	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	47.0	370	377	384	1.65e-103	309
k141_109963_6	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	47.0	370	377	384	1.65e-103	309
k141_109963_6	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	51.3	335	377	388	1.87e-103	309
k141_109963_6	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	51.3	335	377	388	1.87e-103	309
k141_109963_7	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	67.2	232	234	231	5.02e-118	335
k141_109963_7	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	66.8	232	234	231	5.84e-117	332
k141_109963_7	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	65.9	232	234	231	8.29e-117	332
k141_109963_7	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	67.2	232	234	231	2.37e-116	330
k141_109963_7	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	65.5	232	234	231	2.37e-116	330
k141_109963_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	60.3	232	234	232	1.34e-106	306
k141_109963_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	61.0	228	234	232	3.84e-106	305
k141_109963_7	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	56.4	236	234	233	3.31e-93	272
k141_109963_7	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	56.8	236	234	235	2.35e-91	267
k141_109963_7	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	53.8	234	234	232	1.64e-88	260
k141_187882_18	SARG|gb|AEA37904.1|ARO:3003112|lsaC	28.9	201	232	492	1.82e-14	70.9
k141_210751_10	NCBI|WP_012705551.1|1|1|blaR1_gen|blaR1_gen|regulation|2|beta-lactam|beta-lactam|BlaR1_family_beta-lactam_sensor/signal_transducer|AMR|beta-lactam	22.1	362	1042	593	1.78e-17	86.3
k141_210751_23	SARG|gb|APB03216.1|ARO:3003982|LlmA	62.1	285	290	287	3.17e-137	388
k141_198841_10	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	37.5	307	331	351	1.32e-63	204
k141_198841_10	SARG|KF478993.1.gene2.p01	37.1	307	331	350	2.54e-63	203
k141_198841_10	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	37.4	302	331	343	2.32e-62	201
k141_198841_10	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	38.2	296	331	348	2.94e-61	198
k141_198841_10	SARG|gb|AAB05626.1|ARO:3002943|vanHB	36.5	282	331	323	8.25e-61	196
k141_198841_10	SARG|gi|740152780|ref|WP_037997109.1|	35.3	306	331	322	1.59e-60	195
k141_198841_10	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	33.9	316	331	323	2.31e-60	195
k141_198841_10	SARG|Q47748	36.2	282	331	323	4.60e-60	194
k141_198841_10	SARG|YP_002333394	35.8	282	331	323	9.13e-60	193
k141_198841_10	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	35.8	282	331	323	9.13e-60	193
k141_198841_21	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	44.9	225	237	225	1.59e-65	201
k141_198841_21	CARD|gb|AAC73788.1|ARO:3003841|kdpE	44.9	225	237	225	1.59e-65	201
k141_198841_21	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.1	232	237	235	1.86e-47	155
k141_198841_21	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.1	227	237	228	6.06e-47	154
k141_198841_21	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.9	223	237	229	7.00e-46	151
k141_198841_21	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.9	231	237	232	2.14e-45	150
k141_198841_21	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	36.1	227	237	232	3.03e-45	150
k141_198841_21	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.8	223	237	219	4.19e-45	149
k141_198841_21	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.2	227	237	231	4.65e-44	147
k141_198841_21	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.3	227	237	231	1.31e-43	145
k141_198841_22	CARD|gb|CYF42523.1|ARO:3004047|kdpD	30.2	232	358	885	4.81e-22	96.7
k141_198841_22	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.6	225	358	367	8.06e-17	79.7
k141_198841_22	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.6	225	358	368	8.12e-17	79.7
k141_198841_22	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	28.8	250	358	392	2.62e-14	72.4
k141_198841_22	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.8	245	358	365	2.54e-12	66.2
k141_198841_22	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.1	235	358	382	4.87e-12	65.5
k141_198841_22	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	28.1	235	358	382	4.87e-12	65.5
k141_198841_22	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.7	235	358	384	2.80e-11	63.2
k141_198841_22	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	27.7	235	358	384	2.80e-11	63.2
k141_198841_22	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.5	239	358	370	6.36e-11	62.0
k141_153397_8	SARG|gi|488374619|ref|WP_002444004.1|	24.1	431	463	452	1.16e-38	144
k141_153397_8	SARG|gb|CAE00499.1|ARO:3003835|cdeA	25.6	418	463	441	1.27e-37	141
k141_153397_12	CARD|gb|ATC67679.1|ARO:3000838|arlR	43.4	221	226	219	3.20e-50	162
k141_153397_12	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.9	223	226	223	1.91e-34	121
k141_153397_12	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	34.4	221	226	228	2.38e-33	119
k141_153397_12	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	34.5	232	226	252	1.47e-29	109
k141_153397_12	CARD|gb|SIP52035.1|ARO:3004054|Paer_CpxR	32.7	220	226	225	3.32e-28	105
k141_153397_12	CARD|gb|ADM92605.1|ARO:3000553|adeR	31.6	225	226	247	2.21e-26	101
k141_153397_12	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	31.7	221	226	233	2.30e-26	100
k141_153397_12	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	30.5	226	226	229	3.30e-24	95.1
k141_153397_12	CARD|gb|AAD51348.1|ARO:3003066|smeR	31.4	226	226	229	1.32e-22	90.9
k141_153397_12	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.7	225	226	231	1.42e-21	88.2
k141_153397_13	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	25.9	239	442	357	1.53e-15	76.6
k141_153397_13	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	25.9	239	442	357	1.53e-15	76.6
k141_153397_15	SARG|gi|505177635|ref|WP_015364737.1|	25.2	432	454	451	4.87e-38	142
k141_153397_15	SARG|gi|488374619|ref|WP_002444004.1|	25.9	436	454	452	1.22e-36	139
k141_153397_15	SARG|ZP_04679156	25.2	432	454	451	4.31e-36	137
k141_153397_15	SARG|gi|446573690|ref|WP_000651036.1|	25.2	432	454	451	2.70e-34	132
k141_153397_15	SARG|ZP_03986195	25.2	432	454	451	9.57e-34	130
k141_153397_15	SARG|gi|446573692|ref|WP_000651038.1|	25.2	432	454	451	9.57e-34	130
k141_153397_15	SARG|gi|446573695|ref|WP_000651041.1|	25.2	432	454	451	9.57e-34	130
k141_153397_15	SARG|gi|487138435|ref|WP_001629863.1|	25.5	432	454	451	9.57e-34	130
k141_153397_15	SARG|gi|686432388|ref|WP_031921070.1|	25.2	432	454	451	1.31e-33	130
k141_153397_15	SARG|gi|1006223553|ref|WP_061745579.1|	25.2	417	454	451	1.80e-33	130
k141_66030_1	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	49.6	137	144	223	1.41e-48	154
k141_66030_1	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.8	116	144	235	1.29e-24	93.6
k141_66030_1	CARD|gb|ADM92605.1|ARO:3000553|adeR	38.7	124	144	247	3.45e-23	90.1
k141_66030_1	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.9	126	144	219	4.28e-22	86.7
k141_66030_1	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.9	126	144	219	4.28e-22	86.7
k141_66030_1	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.9	126	144	220	4.37e-22	86.7
k141_66030_1	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.9	116	144	228	5.10e-22	86.7
k141_66030_1	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.9	126	144	220	6.13e-22	86.3
k141_66030_1	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.2	116	144	229	1.02e-21	85.9
k141_66030_1	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.4	118	144	219	1.67e-21	85.1
k141_66030_18	SARG|gb|AAC75314.1|ARO:3003578|pmrF	28.6	119	342	322	8.80e-09	55.1
k141_66030_20	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	29.2	209	569	578	2.07e-22	100
k141_66030_20	SARG|gb|AAK76136.1|ARO:3000025|patB	28.7	216	569	588	8.35e-20	92.0
k141_66030_20	SARG|gb|CDO61516.1|ARO:3003949|efrB	25.6	203	569	362	7.32e-19	87.4
k141_66030_20	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.8	209	569	664	9.31e-19	89.0
k141_66030_20	SARG|gb|AVI44920.1|ARO:3004470|poxtA	23.1	216	569	542	6.51e-12	67.0
k141_66030_20	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	23.1	216	569	544	6.53e-12	67.0
k141_66030_20	SARG|FR772051.1.gene9.p01	28.2	195	569	524	1.93e-11	65.5
k141_66030_20	SARG|U82085.gene.p01	22.8	224	569	552	2.48e-10	62.0
k141_66030_42	SARG|gi|948137056|ref|WP_056795395.1|	34.9	304	613	602	3.31e-43	162
k141_66030_42	SARG|gi|748767925|ref|WP_040019608.1|	33.4	305	613	623	1.06e-42	161
k141_66030_42	SARG|gi|496018010|ref|WP_008742581.1|	34.4	311	613	623	1.06e-42	161
k141_66030_42	SARG|gi|944009777|ref|WP_055601444.1|	34.3	315	613	628	2.07e-42	160
k141_66030_42	SARG|gi|860594225|ref|WP_048475168.1|	33.9	313	613	620	3.51e-42	160
k141_66030_42	SARG|gi|664100597|ref|WP_030638327.1|	33.9	304	613	601	3.88e-42	159
k141_66030_42	SARG|gi|503923650|ref|WP_014157644.1|	33.9	304	613	601	3.88e-42	159
k141_66030_42	SARG|gi|664352659|ref|WP_030880307.1|	33.9	304	613	601	5.28e-42	159
k141_66030_42	SARG|gi|662754041|ref|WP_030125200.1|	33.9	304	613	601	5.28e-42	159
k141_66030_42	SARG|gi|505389066|ref|WP_015576168.1|	33.9	304	613	601	5.28e-42	159
k141_66030_43	SARG|gi|944152509|ref|WP_055644808.1|	37.8	262	610	616	2.01e-43	163
k141_66030_43	SARG|gi|748767925|ref|WP_040019608.1|	37.6	250	610	623	2.97e-43	163
k141_66030_43	SARG|gi|1045390184|ref|WP_065479071.1|	39.3	239	610	605	6.12e-43	162
k141_66030_43	SARG|gi|695865802|ref|WP_032778631.1|	38.9	239	610	605	2.11e-42	160
k141_66030_43	SARG|gi|764446018|ref|WP_044369325.1|	38.9	239	610	605	2.87e-42	160
k141_66030_43	SARG|gi|505420018|ref|WP_015607120.1|	38.9	239	610	603	3.82e-42	159
k141_66030_43	SARG|gi|664042835|ref|WP_030582300.1|	38.9	239	610	604	3.86e-42	159
k141_66030_43	SARG|AF170880.4.gene1.p01	39.7	242	610	615	4.36e-42	159
k141_66030_43	SARG|gi|695842130|ref|WP_032755430.1|	38.9	239	610	603	5.20e-42	159
k141_66030_43	SARG|gi|695887424|ref|WP_032788534.1|	38.9	239	610	605	5.32e-42	159
k141_66030_45	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	37.2	86	260	228	5.83e-07	48.1
k141_53900_13	SARG|gi|500465078|gb|EOP76697.1|	28.4	218	302	306	7.77e-29	111
k141_53900_13	SARG|gi|500448961|gb|EOP61695.1|	28.4	218	302	306	1.08e-28	110
k141_53900_13	SARG|P42332	29.4	221	302	306	4.04e-28	109
k141_53900_13	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	29.4	221	302	306	4.04e-28	109
k141_53900_13	SARG|gi|510143239|gb|AGN36970.1|	29.4	221	302	313	4.58e-28	109
k141_53900_13	SARG|YP_001373621	29.9	221	302	318	5.01e-28	109
k141_53900_13	SARG|ABB80128	29.4	221	302	306	5.62e-28	108
k141_53900_13	SARG|ZP_04081918	28.5	221	302	306	1.08e-27	108
k141_53900_13	SARG|AAD21213	29.4	221	302	306	1.51e-27	107
k141_53900_13	SARG|gi|500194536|ref|WP_011867743.1|	30.6	216	302	306	5.60e-27	106
k141_53900_16	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	40.2	219	247	255	6.28e-56	178
k141_53900_16	SARG|gi|835330218|ref|WP_047457825.1|	43.2	220	247	648	1.13e-55	187
k141_53900_16	SARG|YP_001453760	43.2	220	247	648	1.13e-55	187
k141_53900_16	SARG|gi|923061916|ref|WP_053445667.1|	41.8	220	247	648	1.58e-54	184
k141_53900_16	SARG|YP_001571041	42.3	220	247	648	2.20e-54	184
k141_53900_16	SARG|gi|960873409|ref|WP_058345546.1|	42.3	220	247	648	2.20e-54	184
k141_53900_16	SARG|gi|555222481|ref|WP_023215070.1|	42.3	220	247	648	2.20e-54	184
k141_53900_16	SARG|gi|446048047|ref|WP_000125902.1|	41.0	234	247	648	3.06e-54	183
k141_53900_16	SARG|gi|555246906|ref|WP_023230855.1|	41.8	220	247	648	4.26e-54	183
k141_53900_16	SARG|YP_002044935	41.8	220	247	648	4.26e-54	183
k141_53900_18	SARG|gb|AAV85982.1|ARO:3000535|macB	24.6	459	450	644	1.32e-21	96.7
k141_53900_18	SARG|gi|671541568|ref|WP_031525212.1|	22.6	451	450	648	9.90e-18	84.7
k141_53900_18	SARG|gi|495736522|ref|WP_008461101.1|	22.5	457	450	648	1.75e-17	84.0
k141_53900_18	SARG|gi|746243059|ref|WP_039291473.1|	22.5	457	450	648	1.75e-17	84.0
k141_53900_18	SARG|gi|746253210|ref|WP_039301529.1|	22.5	457	450	648	1.75e-17	84.0
k141_53900_18	SARG|gi|736472622|ref|WP_034494292.1|	22.9	458	450	648	1.75e-17	84.0
k141_53900_18	SARG|gi|1035670474|ref|WP_064517458.1|	22.3	457	450	648	2.33e-17	83.6
k141_53900_18	SARG|gi|1035717981|ref|WP_064557480.1|	22.3	457	450	648	2.33e-17	83.6
k141_53900_18	SARG|gi|1035706844|ref|WP_064548272.1|	22.5	463	450	648	7.31e-17	82.0
k141_53900_18	SARG|gi|693066875|ref|WP_032232318.1|	22.1	461	450	648	9.72e-17	81.6
k141_53900_21	SARG|YP_002861121	26.8	97	206	212	2.90e-07	48.1
k141_53900_21	SARG|YP_001779894	25.8	97	206	212	2.49e-06	45.4
k141_53900_21	SARG|YP_001389621	25.8	97	206	212	2.49e-06	45.4
k141_53900_36	SARG|gi|545231858|ref|WP_021531464.1|	28.2	298	323	660	1.55e-34	132
k141_53900_39	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	36.1	319	362	416	1.13e-55	186
k141_53900_39	NCBI|WP_032491462.1|1|1|cfr|cfr|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN_B/TIAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr|AMR|multidrug	34.3	338	362	349	1.19e-55	184
k141_53900_39	SARG|gb|BAD63613.1|ARO:3002816|clbC	33.8	334	362	350	1.71e-55	184
k141_53900_39	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	35.7	319	362	379	2.54e-55	184
k141_53900_39	SARG|AJ249217.gene.p01	34.3	338	362	349	3.30e-55	183
k141_53900_39	SARG|AXY65402.1	31.7	334	362	357	3.62e-52	176
k141_53900_39	SARG|VXQ21601.1	32.6	322	362	344	1.17e-49	169
k141_266498_1	SARG|Q83LR7	48.4	184	216	648	1.03e-48	167
k141_266498_1	SARG|gi|647325472|ref|WP_025760953.1|	48.4	184	216	648	1.03e-48	167
k141_266498_1	SARG|gi|647323678|ref|WP_025760497.1|	48.4	184	216	648	1.03e-48	167
k141_266498_1	SARG|gi|446110305|ref|WP_000188160.1|	47.8	184	216	648	3.81e-48	166
k141_266498_1	SARG|gi|985815823|ref|WP_060876116.1|	49.5	184	216	646	1.91e-47	164
k141_266498_1	SARG|YP_002239469	49.5	184	216	646	1.91e-47	164
k141_266498_1	SARG|gi|695840638|ref|WP_032753940.1|	49.5	184	216	646	1.91e-47	164
k141_266498_1	SARG|gi|556492128|ref|WP_023339842.1|	49.5	184	216	646	1.91e-47	164
k141_266498_1	SARG|gi|446110301|ref|WP_000188156.1|	47.3	184	216	648	1.94e-47	164
k141_266498_1	SARG|gi|974672242|ref|WP_059256507.1|	47.8	184	216	648	2.69e-47	163
k141_266498_2	CARD|gb|AAD51347.1|ARO:3003067|smeS	23.9	205	343	467	1.64e-07	51.6
k141_266498_3	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	37.1	224	227	225	8.59e-37	127
k141_266498_3	CARD|gb|AAC73788.1|ARO:3003841|kdpE	37.1	224	227	225	8.59e-37	127
k141_266498_3	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	32.6	227	227	223	2.77e-34	121
k141_266498_3	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	30.5	236	227	230	1.38e-28	106
k141_266498_3	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.8	237	227	232	2.85e-28	105
k141_266498_3	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.2	235	227	232	5.62e-28	105
k141_266498_3	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	235	227	232	5.62e-28	105
k141_266498_3	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	235	227	232	5.62e-28	105
k141_266498_3	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.8	235	227	232	7.88e-28	104
k141_266498_3	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.5	236	227	232	7.88e-28	104
k141_266498_15	SARG|gi|648667297|ref|WP_026359044.1|	35.5	577	594	605	4.13e-94	300
k141_266498_15	SARG|gi|695842130|ref|WP_032755430.1|	35.3	572	594	603	7.73e-94	299
k141_266498_15	SARG|gi|505420018|ref|WP_015607120.1|	35.3	572	594	603	7.73e-94	299
k141_266498_15	SARG|gi|695865802|ref|WP_032778631.1|	34.1	578	594	605	8.71e-93	296
k141_266498_15	SARG|gi|662129758|ref|WP_030081404.1|	34.6	578	594	605	8.71e-93	296
k141_266498_15	SARG|gi|664170108|ref|WP_030704355.1|	35.1	572	594	603	1.16e-92	296
k141_266498_15	SARG|gi|490068471|ref|WP_003970646.1|	35.1	572	594	603	1.16e-92	296
k141_266498_15	SARG|gi|497748188|ref|WP_010062372.1|	34.1	578	594	605	1.22e-92	296
k141_266498_15	SARG|gi|664085850|ref|WP_030624018.1|	34.6	578	594	605	1.22e-92	296
k141_266498_15	SARG|gi|1045390184|ref|WP_065479071.1|	34.0	583	594	605	1.22e-92	296
k141_266498_16	SARG|gb|AAK76137.1|ARO:3000024|patA	39.0	490	577	564	9.75e-98	307
k141_266498_16	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.4	567	577	582	1.11e-76	253
k141_266498_16	SARG|gi|944152509|ref|WP_055644808.1|	31.4	574	577	616	2.38e-76	253
k141_266498_16	SARG|gi|516574297|ref|WP_017949361.1|	31.1	560	577	620	7.06e-76	251
k141_266498_16	SARG|gi|739906046|ref|WP_037756452.1|	31.1	560	577	620	9.85e-76	251
k141_266498_16	SARG|gi|944009777|ref|WP_055601444.1|	31.6	544	577	628	1.63e-75	251
k141_266498_16	SARG|gi|664556405|ref|WP_031071225.1|	30.9	556	577	602	3.53e-75	249
k141_266498_16	SARG|gi|558888514|ref|WP_023543283.1|	31.2	552	577	615	1.78e-74	248
k141_266498_16	SARG|gi|496018010|ref|WP_008742581.1|	30.9	557	577	623	2.95e-74	247
k141_266498_16	SARG|gi|947982677|ref|WP_056642336.1|	31.2	574	577	626	3.14e-74	247
k141_266498_19	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	30.9	223	237	343	2.15e-25	100
k141_266498_19	SARG|gb|ADZ12699.1|ARO:3005091|RanA	29.1	230	237	258	1.08e-23	94.7
k141_266498_19	SARG|YP_001176128	28.9	242	237	646	4.35e-21	90.5
k141_266498_19	SARG|gi|974588181|ref|WP_059178476.1|	28.5	242	237	646	1.08e-20	89.4
k141_266498_19	SARG|gi|749017716|ref|WP_040076354.1|	30.1	219	237	646	1.08e-20	89.4
k141_266498_19	SARG|gi|976150171|ref|WP_059308384.1|	30.1	206	237	646	9.12e-20	86.7
k141_266498_19	SARG|gi|992390012|ref|WP_061077002.1|	27.0	244	237	648	3.50e-18	82.0
k141_266498_19	SARG|gi|763407609|ref|WP_044264203.1|	27.0	244	237	648	6.41e-18	81.3
k141_266498_19	SARG|gi|968563772|ref|WP_058587854.1|	26.4	239	237	648	8.69e-18	80.9
k141_266498_19	SARG|gi|757782629|ref|WP_043001213.1|	27.0	244	237	648	8.69e-18	80.9
k141_266498_21	SARG|gb|AAC75271.1|ARO:3003952|yojI	27.8	209	253	547	1.74e-16	77.4
k141_266498_21	SARG|gb|CDO61516.1|ARO:3003949|efrB	26.0	181	253	362	4.34e-15	72.8
k141_266498_21	SARG|AXF35727.1	25.1	219	253	497	1.40e-06	47.8
k141_266498_45	SARG|AF155139.2.gene5.p01	28.3	120	168	206	1.10e-07	48.5
k141_266498_45	SARG|gi|670466162|ref|WP_031414939.1|	35.7	70	168	206	5.29e-07	46.6
k141_266498_45	SARG|gi|1028848471|ref|WP_064017434.1|	37.3	67	168	206	2.53e-06	44.7
k141_266498_46	SARG|KF478993.1.gene2.p01	45.1	319	328	350	5.30e-94	282
k141_266498_46	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	43.3	319	328	343	1.71e-93	280
k141_266498_46	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	42.7	323	328	348	1.29e-91	276
k141_266498_46	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	44.5	321	328	351	5.19e-89	269
k141_266498_46	SARG|DQ018711.1.gene4.p01	42.0	312	328	322	5.94e-89	268
k141_266498_46	SARG|gi|740152780|ref|WP_037997109.1|	42.9	312	328	322	1.19e-88	267
k141_266498_46	SARG|gi|737310392|ref|WP_035293250.1|	42.0	312	328	323	2.46e-88	266
k141_266498_46	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	42.2	322	328	337	4.34e-87	264
k141_266498_46	SARG|gi|738848198|ref|WP_036737307.1|	41.7	312	328	323	1.59e-86	262
k141_266498_46	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	41.4	314	328	323	9.03e-86	260
k141_266498_53	SARG|gb|APB03214.1|ARO:3003980|tetA(48)	28.8	177	475	343	1.34e-11	64.7
k141_266498_53	SARG|gb|APB03219.1|ARO:3003986|TaeA	26.9	212	475	648	1.97e-10	62.0
k141_243702_2	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	36.4	239	241	255	5.41e-40	137
k141_243702_15	NCBI|WP_070509550.1|1|1|mef(H)|mef(H)|efflux|2|ERYTHROMYCIN|MACROLIDE|macrolide_efflux_MFS_transporter_Mef(H)|AMR|macrolide	47.2	411	413	412	7.38e-124	363
k141_243702_15	SARG|gb|QQM99829.1|ARO:3007047|mefH	39.6	106	413	109	3.10e-19	81.6
k141_245024_6	CARD|gb|AAC75429.1|ARO:3000833|evgS	27.8	436	856	1197	7.84e-34	139
k141_245024_6	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.2	223	856	361	3.71e-14	73.9
k141_245024_6	CARD|gb|AAG05188.1|ARO:3005068|ParR	28.3	127	856	235	1.77e-08	55.1
k141_245024_10	SARG|gi|921979807|ref|WP_053271336.1|	31.9	235	635	648	2.62e-22	100
k141_245024_10	SARG|gb|AAV85982.1|ARO:3000535|macB	30.2	248	635	644	4.55e-22	99.8
k141_245024_10	SARG|gi|671541568|ref|WP_031525212.1|	30.1	239	635	648	6.09e-22	99.4
k141_245024_10	SARG|gb|AAK76137.1|ARO:3000024|patA	29.4	231	635	564	4.70e-16	80.5
k141_245024_10	SARG|gb|AAK76136.1|ARO:3000025|patB	25.6	246	635	588	1.95e-11	65.9
k141_245024_10	SARG|gb|CDO61516.1|ARO:3003949|efrB	26.3	213	635	362	9.82e-10	59.7
k141_245024_10	SARG|AXF35727.1	25.8	221	635	497	1.97e-06	49.7
k141_245024_22	SARG|gi|488374619|ref|WP_002444004.1|	30.7	437	446	452	8.76e-67	219
k141_245024_22	SARG|gb|AML99881.1|ARO:3001327|mdtK	23.8	282	446	474	7.93e-06	47.0
k141_189855_8	SARG|gi|405945042|pdb|4FU0|A	33.2	376	394	357	1.01e-48	167
k141_189855_8	SARG|gi|752682279|ref|WP_041330231.1|	33.0	373	394	349	1.16e-48	167
k141_189855_8	SARG|DQ212986.1.gene8.p01	33.4	371	394	349	2.28e-48	166
k141_189855_8	SARG|gi|765411304|ref|WP_044689514.1|	33.4	371	394	349	4.46e-48	166
k141_189855_8	SARG|gi|1028100561|ref|WP_063856696.1|	32.4	374	394	349	6.25e-48	165
k141_189855_8	SARG|AAF71281	33.2	371	394	349	1.22e-47	164
k141_189855_8	NCBI|WP_041219811.1|1|1|vanI|vanI|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--(R)-lactate_ligase_VanI|AMR|glycopeptide	31.8	374	394	346	1.31e-44	156
k141_189855_8	SARG|FJ872411.1.gene41.p01	29.0	373	394	352	5.95e-43	152
k141_189855_8	SARG|FJ349556.1.gene6.p01	31.5	371	394	343	6.77e-43	152
k141_189855_8	NCBI|PBI24747.1|1|1|vanG-Cd|vanG-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|D-alanine--D-serine_ligase_VanG-Cd|AMR|glycopeptide	29.0	383	394	366	6.18e-35	131
k141_189855_12	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	29.7	236	327	255	2.47e-25	101
k141_189855_12	SARG|YP_001176128	33.3	243	327	646	1.61e-23	100
k141_189855_12	SARG|gi|974588181|ref|WP_059178476.1|	32.5	243	327	646	3.96e-23	99.0
k141_189855_12	SARG|gi|1032819400|ref|WP_064325534.1|	32.2	242	327	646	9.72e-23	97.8
k141_189855_12	SARG|gi|981224618|ref|WP_059445588.1|	32.9	243	327	646	1.77e-22	97.1
k141_189855_12	SARG|gi|895872463|ref|WP_048979698.1|	32.9	243	327	646	1.77e-22	97.1
k141_189855_12	SARG|gi|836585048|ref|WP_047742322.1|	32.9	243	327	646	1.77e-22	97.1
k141_189855_12	SARG|gi|779866095|ref|WP_045354445.1|	32.5	243	327	646	3.22e-22	96.3
k141_189855_12	SARG|gi|556487375|ref|WP_023335108.1|	32.5	243	327	646	3.22e-22	96.3
k141_189855_12	SARG|gi|1016275448|gb|AMX06027.1|	32.5	243	327	646	3.22e-22	96.3
k141_189855_13	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	26.4	227	379	574	6.38e-13	68.9
k141_189855_13	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	23.4	214	379	550	7.16e-08	53.1
k141_189855_13	SARG|gb|SOX29786.1|ARO:3004730|tva(A)	24.9	169	379	505	1.59e-07	52.0
k141_189855_13	NCBI|WP_014936356.1|1|1|tva(B)|tva(B)|target_protection|2|TIAMULIN|PLEUROMUTILIN|ABC-F_type_ribosomal_protection_protein_Tva(B)|AMR|pleuromutilin	24.8	157	379	504	8.65e-07	49.7
k141_212980_17	SARG|gb|ADZ12699.1|ARO:3005091|RanA	30.5	259	358	258	8.54e-33	122
k141_212980_17	SARG|gi|895865878|ref|WP_048974758.1|	34.5	223	358	646	2.14e-26	109
k141_212980_17	SARG|gi|500448961|gb|EOP61695.1|	30.1	209	358	306	2.24e-26	105
k141_212980_17	SARG|gi|500465078|gb|EOP76697.1|	30.1	209	358	306	3.10e-26	105
k141_212980_17	SARG|gi|507050365|ref|WP_016121371.1|	27.8	209	358	309	2.93e-24	100
k141_212980_17	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.6	224	358	664	1.19e-18	86.3
k141_212980_17	SARG|gb|CDO61516.1|ARO:3003949|efrB	29.4	204	358	362	2.33e-17	81.3
k141_212980_17	SARG|gb|AAK76136.1|ARO:3000025|patB	25.7	230	358	588	1.19e-16	80.1
k141_212980_17	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	27.5	236	358	579	2.22e-14	73.2
k141_212980_17	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	28.4	232	358	579	5.29e-14	72.0
k141_179116_37	CARD|gb|AAC75429.1|ARO:3000833|evgS	29.9	395	1054	1197	3.14e-38	154
k141_179116_37	CARD|gb|ADM92606.1|ARO:3000549|adeS	27.5	262	1054	361	5.13e-21	95.1
k141_179116_37	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	25.6	266	1054	359	1.34e-18	87.8
k141_179116_37	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.6	123	1054	219	5.59e-09	56.6
k141_179116_37	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.6	123	1054	219	5.59e-09	56.6
k141_179116_37	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.6	123	1054	220	5.67e-09	56.6
k141_179116_37	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	27.6	123	1054	220	7.64e-09	56.2
k141_179116_37	CARD|gb|ATC67679.1|ARO:3000838|arlR	26.6	128	1054	219	1.37e-08	55.5
k141_179116_37	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	26.8	123	1054	220	2.02e-07	52.0
